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                                                         ABSTRACT 
 
TIitle: Impact of short course prophylactic antibiotics in poisoning. A randomized double 
blind placebo controlled trial. 
Objective: The primary objective of the study was to evaluate the impact of a short 
course prophylactic antibiotics for the prevention of pneumonia in patients aged fourteen 
years and above who receive gastric lavage for poisoning. 
Design: Single centre, prospective, randomized double blind placebo controlled trial 
Setting: A 2200 bedded tertiary care teaching hospital in South India. 
Participants and methods: A randomized double blind placebo controlled trial was 
performed aiming at the reduction of the incidence of pneumonia in poisoned subjects. 
Between October 31st 2005 and August 1st 2006, one hundred and four patients who 
were hospitalized following poison ingestion and received gastric lavage were included 
in the study.  Of the 104 subjects, 53 were randomized into the prophylactic antibiotic 
group (a combination of three doses of crystalline penicillin 20 lakh units given four 
hours apart and single dose of Levofloxacin 500 mg administered intravenously) and 51 
into the placebo group. Primary outcome was the occurrence of pneumonia as defined 
by the objective criteria. Secondary outcome measures were mortality, duration of 
intensive care and hospital stay and of mechanical ventilation. 
Results: Overall 12 patients fulfilled the objective criteria for pneumonia. Nine were in 
the placebo group and three in the prophylactic antibiotic group. (p= 0.056). The risk 
ratio for patients receiving prophylactic antibiotics compared to patients receiving 
placebo was 0.32 [95% confidence interval, CI=0.09 -1.12].  Although the risk reduction 
in terms of aspiration pneumonia with antibiotics was 68%; this did not reach statistical 
significance. All pneumonia occurred in the mechanical ventilated population. Out of 32 
ventilated patients, 12 developed pneumonia, 3 in the antibiotic group and 9 in the 
placebo group.(p value= 0.014).The risk ratio for patients receiving patients receiving 
prophylactic antibiotics compared to patients receiving placebo in the was 0.29 [95% 
confidence interval, CI = 0.10 - 0.89]. Number needed to treat to avoid an episode of 
pneumonia was 2.3 in the mechanical ventilated population. No differences in the other 
outcome parameters were found. 
Conclusions: Use of short course antibiotic prophylaxis of a combination regimen of 
three doses of intravenously administered crystalline penicillin and a single dose of 
levofloxacin showed a trend towards a reduction in the incidence of pneumonia in 
poisoned patients randomized to the prophylactic antibiotic group. A subgroup analysis 
of mechanical ventilated patients revealed that prophylaxis is probably an effective 
strategy for the prevention of pneumonia in mechanically ventilated poisoned subjects. 
These observations justify the conduct of a larger prospective study to evaluate the role 
of prophylactic antibiotics in poisoned patients. 
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                                 Introduction 
 
 
               Poisoning remains a major health problem despite regulatory 
intervention and medical advances. Worldwide, more than three million 
poisoning cases with a quarter million deaths occur annually, of which, 
99% of fatal poisonings occur in developing countries.1 In recent times, 
several advances have been made in the discipline of clinical toxicity that 
have significantly improved the treatment modalities and methods for 
poison treatment. However deaths due to poisoning are on a constant rise 
particularly in developing countries where poisoning is associated with a 
high case fatality rate.2,3 Several factors contribute to the high mortality 
rate in poisoning; one of the important causes being respiratory failure 
complicating aspiration pneumonia.4,5,6 
 
              Aspiration is a common event in poisoned subjects and carries 
with it the risk of development of aspiration pneumonitis and pneumonia. 
Pneumonia rates in poisoned subjects vary from 4 to 50%.7,8,9 Several risk 
factors contribute to the development of aspiration pneumonia and gastric 
decontamination is one among them.8,9 Aspiration pneumonia results in 
substantial morbidity and mortality and leads to increased use of 
antibiotics, mechanical ventilation, prolonged hospital stay and increased 
costs of treatment.9-11 
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                 Any intervention that can reduce the incidence of aspiration 
pneumonia and the morbidity and mortality associated with it is worthy of 
study.  One such intervention would be the use of prophylactic antibiotics 
to reduce the development of pneumonia. However there exists a 
difference of opinion among physicians on the role of prophylactic 
antibiotics. Clinicians in developing countries often prefer to start 
antibiotics in poisoned subjects12 considering the severity of the poisoning 
and the magnitude of the morbidity imposed by aspiration pneumonia. 
However this practice is not evidence based. In fact, to the best of our 
knowledge, there has been no randomized controlled trial that has 
evaluated the impact of prophylactic antibiotics in the setting of poisoning.  
Short course systemic prophylactic antibiotics in other clinical settings13,14 
have been shown to reduce the risk of pneumonia and associated 
morbidity.  Hence we decided to conduct a randomized controlled trial to 
evaluate the impact of a short course prophylactic antibiotic regimen for 
prevention of pneumonia in the setting of poisoning. 
Hypothesis 
Hypothesis for the study was as follows. 
Would the administration of a short course of systemic antibiotic 
prophylaxis (three doses of crystalline penicillin 20 lakh units at four hourly 
intervals and single dose of Levofloxacin 500 mg intravenously 
administered) reduce the incidence of pneumonia in adult patients 
presenting with poisoning and receive gastric lavage. 
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         Review of the literature 
               Poison and poisoning have been known since time immemorial.  
The use of poison dates back to the earliest humans, who used animal 
venoms and plant extracts for hunting, warfare and assassination. The 
Ebers papyrus (circa 1500 B.C) contains information pertaining to many 
recognized poisons including hemlock (the state poison of the Greeks), 
aconite (a Chinese arrow poison), opium and metals such as lead, copper 
and antimony. There are several references to poisons and their use as 
means of suicide or as a weapon for homicide in the literature of ancient 
Greece.15,16      
               Poison may be defined as a substance which when 
administered, inhaled or swallowed is capable of acting deleteriously on 
the body.15,16 Probably one of the best known definitions of poison is that 
by Paracelsus15,16 [more properly known as Theophrastus Phillippus 
Aureolus Bombastus von Hohenheim], alchemical genius of the middle 
ages and father of modern toxicology. Paracelsus over 400 years ago had 
stated, “All substances are poisons; there is none which is not a poison. 
The right dose differentiates a poison and a remedy.”  
              In recent times, owing to the vast developments made in the field 
of chemical technology, a significant number of new compounds used in 
the field of trade, industry and medicine have been added as poisonous 
substances. Poisoning with such compounds either accidental or suicidal 
has become common due to easy availability and low cost. Increasing  
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mortality and morbidity associated with poisoning is a growing concern 
among medical fraternity of the developing world. The case fatality for self-
poisoning in the developing world is commonly 10–20%, but for particular 
pesticides it may be as high as 50–70%. 3 
 
              The causes of the high case fatality are multifactorial but include 
the high toxicity of locally available poisons, difficulties in transporting 
patients across long distances to hospital, the paucity of health care 
workers compared with the large numbers of patients, and the lack of 
facilities, antidotes, and training for the management of pesticide- 
poisoned patients.3,16 The problem is compounded by a lack of proven 
interventions with which to develop treatment protocols. Complications 
such as seizures, arrhythmias, hypotension, respiratory failure and 
pneumonias compound the problem and contribute to the increased 
mortality. As mentioned earlier, aspiration pneumonia in poisoned subjects 
is associated with an increased use of antibiotics, antimicrobial resistance, 
super infections, prolonged hospital stay and increased costs of treatment.  
It has been shown previously that drug overdose is a common cause of 
aspiration, ranging from 29% to 50 % of patients in studies conducted in 
intensive care units. 9,18-19 Identification of the predisposing risk factors and  
strategies such as prophylactic antibiotics may help lessen the burden of 
pneumonia. 
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Epidemiology 
 
GLOBAL BURDEN OF POISONING 
                        Poisoning is an important health problem worldwide, 
though the type of poison and the associated morbidity and mortality may 
vary from place to place and change over a period of time.  According to 
WHO more than three million cases of poisoning occur worldwide 
annually, of which, 99% of fatal poisonings occur in developing countries 
particularly among agricultural workers.1 In developed nations like the 
United Kingdom, about 15-20% of the workload of medical units and 
emergency departments are due to self poisoning. 20,21 Acute poisoning is 
an important medical emergency and major cause of morbidity and 
mortality in developing countries like India.  It is reported that 1 to 1.5 
million cases of poisoning occur every year in India. 22 Poisoning imposes 
a health burden which differs from many other common conditions 
affecting public health. Apart from 68.2 hospitalizations per year per 
100,000 populations23 and subsequent hospital stay and costs, poisoning 
has significant impact on the after effects in the patients’ and caregivers’ 
lives. These effects may be reflected not only in the mental and the 
physical health of the victim but also in the legal, social and occupational 
health of the society at large. 
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PROFILE OF POISONING 
 
                A detailed knowledge about the nature and magnitude of the 
poisoning cases in a particular area is not only important for early 
diagnosis and prompt treatment but also is essential for introducing new 
and evaluating old treatment measures. In developing countries deliberate 
self harm account for most cases of poisoning (Figure1).3,24,25 Recent 
adverse life events, interpersonal stress and relationship difficulties, 
severe financial distress, unemployment, mental illness, chronic illness, 
use of alcohol, lack of religious faith etc are the major risk factors reported 
for deliberate self harm. 
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Figure.1. Comparison of methods used for fatal self harm in England & Wales, 
Australia, and Asia. 3, 24,25 
               Tablet overdose is the most common cause of poisoning in the 
developed world. In the United Kingdom, paracetamol remains the most 
common drug taken in overdose (50% of intentional self poisoning 
presentations).26,27 In developing countries3 like India and Sri Lanka, 
majority of the poisoning are due to organophosphate insecticides used 
for agricultural purposes. This is mainly because of their wide usage and 
easy availability. In India several profile studies on poisoning have been 
conducted and in most series poisoning was intentional with a male 
preponderance.  Insecticides such as organophosphates were the most 
common compounds involved in poisoning. Profile of poisoning in different 
parts of the country28-31 is summarized in the table below (table.1). In the 
Christian Medical College and Hospital, Vellore organophosphate 
poisoning accounts for 12% of all medical intensive care unit admissions 
and 75% of all poisonings. 34 
  
MORTALITY               
 
               Everyday around the world, almost 700 people die from 
poisonings and for every person that dies, several thousands more are 
affected by poisoning.1,35 In developed nations like the United Kingdom, 
nearly 4000 deaths occur per year due to poisoning.21   In India nearly 
50,000 die annually due to poisoning.35  
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Region No of 
patient
s 
Males  
( % ) 
Intenti- 
onal 
(%) 
 Common Poisons 
 involved 
Mortality (%) 
Delhi 
1999-2002 
Srivastava 
et al28 
2719 57 53 Household- 44.1% 
Drugs- 18.8% 
Pesticides- 12.8% 
(aluminium phosphide 
most common) 
Not available [N.A] 
Rohtak 1994 
Siwach SB 
et al29 
 
559 66 91.4 Aluminium Phosphide-
67.8% 
Organophosphates- 
13.9% 
Zinc phosphide- 4.3% 
33.82% 
Aluminium 
phosphide-67.6% 
Mangalore  
2001-2003 
Singh et al30 
33207 70 72 Agrochemical -49 
Drugs-17% 
Alcohols-13% 
15% 
Organophosphate-
65% 
Aluminium 
phosphide-15% 
Mangalore 
1999-2003 
Unnikrishna
n et al31 
 
546 69.6 68 Organophosphates- 
35.7% 
Alcohols-12.4% 
Drugs-11.8% 
 
Not available [N.A] 
Yavatamal 
Maharashtra 
1997-200132 
4245 67 63.4 Organophosphate-
23.1% 
Alcohol-21% 
Organochlorine-12% 
 
28.5% 
Organophosphate-
43.3% 
Thomas et al 
Christian 
medical 
college, 
Vellore33 
1584 M:F 
5:4 
90.6% Organophosphate-
49.4% 
Drugs-22.5% 
Household chemicals-
10.2% 
Plant poisons-5.6% 
 
3.3% 
Organophosphate-
38.4% 
 
Table. 1. Pattern of poisoning in India 
 
             Case fatality rate for poisoning varies among the different parts of 
the world. For every 1000 self poisoning patients admitted to European 
hospitals, fewer than five die36. For every 1000 admitted to rural Asian 
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hospitals, 100-200 die.3 Organophosphate compounds were responsible 
for the majority of deaths in most series of self poisoning cases in rural 
 
 areas of the developing world. The reported fatality in hospital based                                
surveys3 was as high as 46%. Mortality rate for poisoning deaths in 
various studies conducted in India is reported between 3.3% and 34%.29,33 
Mortality in poisoning depends on the severity of poisoning; mechanisms 
of toxicity and other complications such as aspiration pneumonia. 
Mechanisms of toxicity and mortality rate of common poisonings 
encountered in the Christian Medical College Hospital (CMCH), Vellore 
are illustrated in the figure below (figure.2). A more recent report from 
CMCH37 showed a mortality of around 14% in organophosphate poisoned 
patients admitted to the medical intensive care unit. 
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                    Pneumonia in poisoning 
 
 
                In recent times, several advances have been made in the field 
of toxicology which has increased our knowledge of the chemistry of 
poisons, modes of toxic action and detoxification processes as well as 
specific molecular events in the poisoning process.  All these advances 
have revolutionized the fundamentals of poisoning care (figure 3). 
However the mortality and morbidity associated with acute poisoning, 
especially in developing countries, remains high.         
There are many different direct causes of death in poisoning- 
hypotension, paralysis, respiratory failure, arrhythmia, electrolyte 
imbalance etc. Among them, respiratory failure4,5 is considered to be the 
one of the most important causes of morbidity and mortality in acute 
poisoning especially with compounds such as organophosphates; the 
commonest poison ingested in this region. Respiratory failure has been 
shown to correlate with mortality in several studies. Patients with 
poisoning may have respiratory failure for many reasons, including 
aspiration of gastric contents, excessive secretions, pneumonia, sepsis 
and adult respiratory distress syndrome. Aspiration pneumonia is an 
important cause for respiratory failure with consequences of increased use 
of antibiotics, prolonged duration of mechanical ventilation and hospital 
stay, and increased costs of treatment.10 
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Figure.3. Fundamentals of Poisoning Management38 
    
                                              
 
I. SUPPORTIVE CARE 
 Airway protection 
 Oxygenation/ventilation 
 Treatment of arrythmias 
 Hemodynamic support 
 Treatment of seizures 
 Correction of temperature 
abnormalities 
 Correction of metabolic 
derangements 
 Prevention of secondary 
complications 
II. PREVENTION OF FURTHER 
POISON ABSORPTION 
• Gastrointestinal decontamination38 
- Ipecac 
- Gastric lavage 
- Activated charcoal 
- Whole bowel irrigation 
- Catharsis 
- Dilution 
- Endoscopic/surgical removal 
 
• Decontamination of other sites 
- Eye and skin 
decontamination 
 
 POISONED  
  PATIENT 
III. ENHANCEMENT OF POISON 
ELIMINATION 
 Multiple dose activated charcoal 
 Forced diuresis 
 Alteration of urine pH 
 Chelation 
 Extracorporeal removal 
- peritoneal dialysis 
- hemodialysis 
- hemoperfusion 
- hemofiltration 
- plasmaphersis 
- exchange transfusion 
 Hyperbaric oxygenation 
IV. ANTIDOTES 
 Neutalisation by antibodies 
 Neutralisation by chemical 
binding 
 Metabolic antagonism 
 Physiologic antagonism 
V. PREVENTION OF 
REEXPOSURE 
 Psychiatric assessment 
 Adult education 
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Aspiration pneumonitis versus aspiration pneumonia 
                Aspiration can be divided broadly into two distinct entities with 
overlapping features -- aspiration pneumonia and aspiration pneumonitis.               
Aspiration pneumonitis is a chemical injury to the lung parenchyma by the 
acid contents of the stomach. [27] In contrast, aspiration pneumonia differs 
in being a bacterial infection resulting from oropharyngeal flora being 
aspirated. Bacterial colonization and sepsis are common sequelae in 
aspiration pneumonia. However bacterial colonization and sepsis may 
also occur in severe aspiration pneumonitis. This is because resulting lung 
inflammation can contribute to a subsequent infection, since the material 
aspirated may contain anaerobic or other unusual causes of pneumonia. 
Experimental studies provide adequate data for this. 
 
              Experimental studies40,41 have shown that the severity of acute 
lung injury is related not only to the volume and acidity of the aspirate but 
also to its composition.  Knight et al40 compared the inflammatory potential 
of small gastric particles to acidic lung injury and examined their 
interaction. Results of their experimental study showed that the aspiration 
of gastric contents (i.e, acidified food particles) lead to inflammatory 
changes in lung with capillary leak, release of inflammatory cytokines and 
chemokines, cellular infiltration, surfactant dysfunction, hypoxemia and 
oxidative injury of greater magnitude than those resulting from the 
aspiration of acid or gastric particles alone.  Although the acidity of the 
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 stomach generally prevents the growth of bacteria, aspiration of 
nonsterile gastric contents can lead to the development of pneumonia. 
This occurs, for instance, in patients receiving antacids who aspirate 
pathogenic organisms colonizing the less acidic stomach or more 
commonly, following concomitant aspiration of the oropharyngeal flora. 
The above data is summarized in the figure below (figure. 4) 
 
 
Figure. 4. Schematic representation of events that may occur following 
aspiration. 
               Subsequent studies have shown that aspiration insult primes the 
host to an exuberant inflammatory response when confronted with an 
ensuing infectious challenge; and the resulting inflammatory milieu and 
injury adversely influences the host’s ability to clear bacteria. Rotta et al42                                                  
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established an animal model of secondary bacterial pneumonia following 
gastric aspiration and described possible mechanisms involved in the 
suppressed antibacterial defenses following the initial pulmonary insult. In 
this controlled in vivo laboratory study gastric aspirate (1.2 mL/kg of 
saline, pH 1.25, and 40 mg/ml sterile rat gastric particles) or an equal 
amount of normal saline (pH 5.3) was instilled intratracheally into study 
animals. One minute after this insult, animals received an intratracheal 
instillation of either 5.6 x 105 colony-forming units of Escherichia coli or an 
equal volume of normal saline. Animals that received gastric aspirate 
(followed by normal saline or E. coli) had increased injury as assessed by 
significant reductions in oxygenation and elevations in bronchoalveolar 
lavage albumin. At 24 hours, animals that received gastric aspirate 
inoculation followed by E. coli had significantly higher pulmonary bacterial 
counts compared with animals that received E. coli alone. Gastric 
aspiration injury followed by bacterial inoculation also resulted in acute, 
but transient, increases in tumor necrosis factor-alpha, interleukin-1 beta, 
cytokine-induced neutrophil chemoattractant-1, and macrophage 
inflammatory protein-2 and more sustained elevations of monocyte 
chemoattractant protein-1 and interleukin-10.  These results suggest that 
following gastric aspiration lung injury increases and bacterial clearance 
decreases. Similar pulmonary inflammatory milieu is likely to occur 
following aspiration in a poisoned subject with consequent risk for 
bacterial pneumonia.                            
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Pneumonia incidence and Diagnosis 
                There exists a wide variation in the reported rates of pneumonia 
following poisoning in different studies which probably reflect the 
differences in the type of poison ingested, severity of poisoning, level of 
consciousness and various other factors. The reported incidence varies 
from 4% to 50% in different studies.4-6,8,9,17-19,43-46  An audit of 204 patients 
admitted to our institution following poisoning over a period of 10 months 
during 2004-2005  revealed 35% incidence of pneumonia within four days 
of hospitalization (unpublished local epidemiological data) 
 
                There are no specific diagnostic tests for aspiration pneumonia. 
The diagnosis in most settings is usually based on new findings of 
hypoxemia, pulmonary infiltrates in gravity dependant lung regions, fever, 
and leucocytosis. Microbiological diagnosis is often difficult because of the 
problems in obtaining specimens of deep respiratory tract without 
contamination by oral flora and the often limited laboratory capacity for 
isolation of anaerobic organisms.  
 
               Several authors4,8,19,47,48 have used a constellation of clinical 
findings for the diagnosis of pneumonia. The criteria for aspiration for most 
authors were modifications of those defined by Lorber and Swenson49 and 
Bartlett et al50: namely, the presence of alveolar infiltrates on the chest 
radiograph and either witnessed aspiration or risk factors for aspiration. 
Clinical criteria used in various studies are tabularized below.  
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Tsao et al4 new pulmonary infiltrates not explained by any other means and with at 
least two of the following: (1) raised white blood cell count; (2) purulent 
bronchial secretions; and (3) positive Gram stain and culture 
El-Solh et al47 (1) the development of new radiographic infiltrate compatible with 
pneumonia; (2) the presence of symptoms or signs suggestive of lower 
respiratory tract infection (one major criteria of either cough, sputum 
production, or fever above 38°C or  below 35.5°C, plus two minor criteria 
of pleuritic chest pain, dyspnea, delirium, increased alveolar arterial 
gradient, or white blood cell count > 12,000/mm3, and/or left shift or 
leukopenia < 3,000/mm3) necessitating mechanical ventilation; and (3) 
the presence of risk factors for oropharyngeal aspiration 
Terpenning et 
al48 
Fever>99.5 F, WBC showing a rise of 5000 cells/mm,opinion of 
attending physician that pneumonia was present, auscultatory findings, 
characteristic symptoms, sputum production, dyspnoea, chest pain 
Marick et al19 the presence of alveolar infiltrates on the chest radiograph and either 
witnessed aspiration or risk factors for aspiration  
Liisanantti et 
al8 
the presence of new infiltrates on chest radiography associated with 
leucocytosis and fever or purulent tracheal secretions within 48 h after 
admission to the hospital. 
 
 
Table.2 Clinical criteria for aspiration pneumonia in various studies 
Clinical criteria for the diagnosis of pneumonia in our study was modified 
from the above criterion and included 
Two or more serial chest radiographs with at least one of the following: 
 New or progressive and persistent infiltrate  
 Consolidation 
 Cavitation   
And, at least one of the following: 
  Fever (> 38°C or >100.4°F) with no other recognize d cause 
 Leukopenia (<4,000WBC/mm3) or leukocytosis (>12,000 
WBC/mm3) 
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 More than 10% of band forms 
And at least two of the following: 
• New onset of purulent sputum, or change in character of sputum, or 
increased respiratory secretions, or increased suctioning requirements 
• New onset or worsening cough, or dyspnea, or tachypnea 
• Rales or bronchial breath sounds 
• Worsening gas exchange (e.g., oxygen desaturations [e.g., PaO2/FiO2 < 
240], increased oxygen requirements, or increased ventilation demand) 
OR a modified clinical pulmonary infection score more than 6.51 
 
                 It is often difficult to differentiate pneumonia due to poisoning 
and decontamination from other forms of pneumonia resulting from 
aspiration such as the early onset ventilator associated pneumonia, as the 
findings often overlap. Ventilator associated pneumonia is defined as 
pneumonia occurring after 48 hours after intubation.52 However a subset 
of patients may have pneumonia occurring within the first four days of 
intubation, known as the early onset pneumonia.52 Difficulty in 
differentiation is also compounded by the fact that aspiration pneumonia 
due to lavage may present after 48 hours of exposure. For the purpose of 
this study, all pneumonias occurring within four days were assumed to be 
due to aspiration occurring at the time of decontamination. 
Mortality in aspiration pneumonia 
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               Mortality in aspiration pneumonia in various setting varies from 
21%-62%.53,54 Factors associated with death from aspiration pneumonia in 
a study  were: altered mental status, endotracheal intubation, tachycardia, 
and hypoxemia. 55 
 
Risk factors for aspiration pneumonia and aspiration pneumonitis in 
poisoned patients 
                       Risk factors for pneumonia and pneumonitis are numerous 
and include age, sex, place of admission (ward, intensive care unit, etc), 
severity of underlying disease, emesis, gastric lavage, activated charcoal, 
level of consciousness, airway instrumentation (intubation, reintubation, 
etc) and type of poison. Identification of the risk factors may allow the 
early identification of these patients for appropriate observation and 
management.  Summary of risk factors for pneumonia and pneumonitis in 
studies with high incidence of pneumonia is tabulated below.8,56-60                
 
               A retrospective study conducted by J. Liisanantti et al8 analyzed 
257 patients admitted with severe self-poisoning over a period of eleven 
years in the intensive care unit of University Hospital, Oulu, Finland. 
28.4% of 257 patients fulfilled the clinical criteria of aspiration pneumonia 
in the study.  The risk factors for development of aspiration pneumonia in 
this study included the use of gastric lavage or activated charcoal in the 
case of a non-intubated unconscious patient. [Odds ratios of 2.7 
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(confidence interval, CI 0.8-9.3) and 3.7 (CI 1.01-12.5), respectively] and 
delay in intubation. 
 
 Host factors Intervention factors 
Liisantti et al8  use of gastric lavage or 
activated charcoal in a non-
intubated unconscious 
patient [ odds ratios of 2.7 
(confidence interval, CI 0.8-9.3) 
and 3.7 (CI 1.01-12.5)] 
delay in intubation 
Isbister GK et al56 Older age 
Glasgow coma scle,GCS < 15 
(odds ratio, OR 3.14;  
  95% CI  1.87-5.27), 
Emesis (OR, 4.17; 95% CI, 2.44- 
  7.13), 
Seizures  
Ingestion of tricyclic 
 antidepressants 
Delayed presentation to  
hospital (delay of >24 hrs [OR, 4.42; 
95% CI, 2.42-8.10]). 
 
 
Christ et al57 Low GCS 
Ingestion of opiates 
Elevated white blood cell counts 
 
Vucinic et al58 Sex 
Chronic alcohol intake 
Underlying illnesses 
Coma 
Central venous catheter 
Vasopressor 
H2 receptor blocker 
Corticosteroids 
Adnet et al59,60 Low GCS  
Prone body position at the time 
of discovery 
 
Merigian et al10  Gastric lavage 
 
Table.3. Risk factors for aspiration and aspiration pneumonitis in various studies 
Gastrointestinal decontamination and aspiration pneumonia 
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         Two of the common methods for gastro intestinal decontamination 
are gastric lavage and activated charcoal.  Gastric lavage39 involves the 
placement of a wide bore (36-40 French) orogastric tube followed by 
instilling and then removal of several liters of water in aliquots to wash out 
the stomach contents.  
 
             Gastric lavage is fraught with potential complications39 which 
include pneumonia, laryngospasm, hypoxia, hypercapnia, fluid and 
electrolyte imbalance; and mechanical injury to, or perforation of throat, 
esophagus and stomach. However the most common complication of 
lavage is aspiration pneumonia. In some patients this may be due to 
performing the procedure in comatose patients with an unprotected 
airway.  
 
             Liisantti et al8 examined retrospectively the medical records of 257 
patients with self-poisoning, and calculated an odds ratio of 2.7 (CI 0.8–
9.3) for the development of aspiration pneumonitis when gastric lavage 
was performed in unconscious non-intubated patients.  
 
              Merigian et al10 prospectively studied the effect of gastric 
emptying and activated charcoal upon clinical outcome in acutely self-
poisoned patients. Results of the study showed gastric lavage to be 
associated with a higher prevalence of aspiration pneumonia (P=.0001) 
and medical intensive care unit admissions (P =0.0001). 
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            Some authors, however, have found a lower incidence of 
pneumonia after decontamination. Moll et al7 found administration of 
activated charcoal to intubated overdose patients to be associated with a 
low incidence of aspiration pneumonia 
 
  Microbiology of Aspiration pneumonia 
                       There is conflicting information about the range of 
organisms responsible for aspiration pneumonia. The role of anaerobic 
organisms from the mouth seemed to be established in the 1970s and 80s 
using transtracheal and pleural aspiration to obtain specimens from the 
lower respiratory tract, avoiding the problem of contamination of 
expectorated sputum by normal mouth flora.  
 
                        Most patients with aspiration pneumonia have infection 
with multiple organisms.49-50Anaerobic organisms were found to be the 
predominant pathogens, isolated alone or with aerobes.49,50,62 More recent 
studies18,19 have reported a lower frequency of anaerobic organisms as 
causative pathogens in aspiration pneumonia. However, these studies did 
not use comparable sampling methods or detailed anaerobic culture 
methods. The anaerobic pathogens most frequently isolated in patients 
with aspiration pneumonia include Bacteroides, Peptostreptococcus, 
peptococcus and Fusobacterium species. Streptococcus pneumoniae, 
Staphylococcus aureus, Hemophilus influenzae, and Enterobacteriaceae 
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predominated in patients with a community-acquired aspiration syndrome, 
whereas gram-negative organisms, including P. aeruginosa, predominated 
in patients with a hospital-acquired aspiration syndrome in a recent 
study.19 
                     Identifying organism(s) responsible for pneumonia is often 
attempted but not achieved in clinical practice for a number of reasons. 
These include contamination of sputum specimens with oropharyngeal 
flora, previous treatment with antibiotics and the difficulties using invasive 
techniques (such as bronchoscopy, transtracheal and transthoracic 
aspiration) that are more reliable at isolating pathogens. Anaerobic 
pathogens are difficult to identify even with good laboratory expertise.  
 
Treatment of aspiration pneumonia 
                    The choice of antibiotics should depend on the setting in 
which the aspiration occurs. Recommended antibiotic regimens62 for 
community-acquired aspiration pneumonia include penicillin, clindamycin, 
beta-lactam and beta-lactamase inhibitor combinations such as ampicillin 
sodium and sulbactam sodium or penicillin plus metronidazole. 
Monotherapy with metronidazole has been associated with a high clinical 
failure rate despite good in vitro activity against most anaerobes. The 
newer fluoroquinolones (eg, levofloxacin, gatifloxacin, moxifloxacin) have 
reasonable anaerobic activity and achieve high concentrations in lung 
tissue and endobronchial secretions. Trimethoprim-sulfamethoxazole and 
aminoglycosides have little or no activity against anaerobes. A recent11 
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review recommended the use of antibiotic agents with activity against 
gram-negative organisms, such as third-generation cephalosporins, 
fluoroquinolones, and piperacillin in addition to the gram positive and 
anaerobic coverage. Corticosteroids have not been found to be useful in 
the management of aspiration pneumonitis and pneumonia.62 
 
         
Table.4. EMPIRICAL ANTIBIOTICS RECOMMENDED FOR THE MOST COMMON 
ASPIRATION SYNDROMES11 
Antibiotic prophylaxis- Basis 
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               Antibiotic prophylaxis are often indicated in patients who 
have no evidence of infection but who have been or are expected to be 
exposed to bacterial pathogens under circumstances that constitute a 
major risk of infection. The basic principles of antibiotic prophylaxis are as 
follows. 1.The risk or potential severity of infection should be greater than 
the risk of side effects.  2. Prophylaxis should be given for the shortest 
period necessary to target infections.  3. Antibiotics should be given before 
the expected period of risk or as soon as possible after contact (post 
exposure prophylaxis). Examples of antimicrobial prophylaxis being 
infective endocarditis prophylaxis, mupirocin prophylaxis for recurrent 
staphylococci infections, prophylaxis for cystitis, recurrent cellulitis with 
lymphoedema, traveler’s diarrhea, neutropenic patients, spontaneous 
bacterial peritonitis, contacts of patients with meningococcal meningitis 
and various other surgical settings. 
 
                From the above discussions, it would be clear that poisoning is 
common and the magnitude of the problem imposed by aspiration in 
poisoning is often severe enough to warrant a preventive approach. Many 
authors do not recommend prophylactic antibiotics in the setting of 
poisoning. However the recommendations are not evidence based.  In 
fact, to the best of our knowledge, there has been no randomized 
controlled trial that has evaluated the impact of prophylactic antibiotics in 
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the setting of poisoning.  Short course systemic prophylactic antibiotics in 
other clinical settings13,14 of aspiration have been shown to reduce the risk 
of pneumonia and associated morbidity. 
 
                In a recent randomized controlled trial13 done in comatose 
patients admitted to an intensive care unit with head injury and stroke, use 
of short course of prophylactic antibiotic showed reduction in the risk of 
pneumonia, hospital and intensive care unit stay. In the same clinical trial 
protective effect against pneumonia was also observed in control subjects 
who had previously received prophylactic antibiotics.  
               
                  Effect of short course prophylactic antibiotics on the incidence 
of early onset pneumonia in critically ill comatose patients were studied in 
a single centre prospective open study.14 A three day prophylaxis with 
ampicillin –sulbactam [3gm every 6 hours for three days] significantly 
reduced the occurrence of early onset pneumonia in critically ill comatose 
mechanically ventilated patients 
 
               In another randomized placebo controlled double blinded clinical 
trial63 in critically ill patients, short course prophylactic antibiotic reduced 
the incidence of four most common ICU infections including pneumonias.  
 
               Is an ounce of prevention worth a pound of cure? The answer 
depends on how effective, toxic, and costly the ounce of prevention is 
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relative to the pound of cure. Prophylactic antibiotics have been found to 
be effective in various settings described above. The other side of the coin 
is the fact that antibiotic prophylaxis has the potential for serious adverse 
effects. Rates of antibiotic resistance are increasing in all hospitals.64 The 
prevalence of antibiotic resistance in any population is related to the 
proportion of the population that receives antibiotics and also to the total 
antibiotic exposure.65 Prolonged use of broad spectrum antibiotics merely 
alter the normal flora and may lead to increasing frequency of antibiotic 
resistance among subsequent hospital acquired infections. Use of 
prophylactic antibiotics has also risks of side effects. The most significant 
adverse event associated with penicillin, one of the agents used in this 
study, is hypersensitivity reactions which can range from a troublesome 
rash to a life threatening anaphylactic reactions. One-to-ten per cent of 
patients report a penicillin allergy although many of these will not be 
confirmed if subjected to the appropriate test.66 More importantly, the 
chance of a penicillin reaction following administration of the drug is in the 
range of 0.7-5 %.67 An additional problem with the use of prolonged 
antibiotics is the dramatic increase in the number of cases of colitis 
caused by Clostridium difficile.68 The prevalence of C. difficile infection is 
related to total antibiotic usage.68  Use of short course antibiotics may 
have a lower impact on the emergence of bacterial resistance and 
problem of antibiotic induced colitis. 
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                 There is no literature on the dose and duration of antibiotic 
prophylaxis in this group of patients (i.e. poisoned subjects who receive 
gastric lavage). Due to this paucity of data, we decided to choose a short 
course prophylaxis regimen which was akin to infective endocarditis 
regimen. We chose penicillin because it was cheap, widely available and 
offers protection against gram positive organisms as well as anaerobes. 
Postulate in using additional doses of penicillin was that it would eliminate 
the incubating bacteria and afford anaerobic coverage. Levofloxacin is one 
of the agents recommended recently for treatment of aspiration 
pneumonia11 and was chosen to provide additional gram negative 
coverage since gram negative bacteria are being increasingly found in 
aspiration syndromes.  Use of Levofloxacin alone would not have given 
sufficient anaerobic cover.  
 
           In summary, poisoning appears to be a major health problem with 
significant morbidity and mortality. Pneumonia in poisoned subjects adds 
to the morbidity and mortality. Measures to prevent pneumonia may be 
beneficial. Short course systemic prophylactic antibiotics in other clinical 
settings13,14 have been shown to reduce the risk of pneumonia and 
associated morbidity. Hence we endeavored to conduct a randomized 
controlled trial to evaluate the impact of a short course prophylactic 
antibiotic regimen for prevention of pneumonia in the setting of poisoning. 
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                                AIMS AND OBJECTIVES 
 
 
 
 
The study was undertaken with the following objectives. 
 
 
 
PRIMARY OBJECTIVE: 
 
 To evaluate the impact of a short course systemic antibiotic 
prophylaxis for the prevention of pneumonia in poisoned patients 
aged fourteen years and above who receive gastric lavage. 
 
 
SECONDARY OBJECTIVES: 
 To assess the impact of a systemic antibiotic prophylaxis on 
mortality, duration of intensive care unit and hospital stay and of 
mechanical ventilation in poisoned patients aged fourteen years 
and above who receive gastric lavage. 
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PARTICIPANTS AND METHODS 
Study design 
               The study was a prospective randomized double blind 
placebo controlled trial over a period of 9 months between October 31st 
2005 and August 1st 2006. The study was conducted in the emergency 
ward, the medical wards and the medical intensive care unit of a tertiary 
teaching hospital in India (Christian Medical College and Hospital, 
Vellore). All patients aged fourteen years of age and above presenting to 
the emergency department following ingestion of a poison and received 
gastric lavage were eligible for recruitment in the study. Eligible patients 
were screened for the inclusion and exclusion criteria.   
                  The study was performed in accordance with the Declaration of 
Helsinki and subsequent amendments and under the regulations of Good 
Clinical Practice. The study was approved by the Research committee as 
well as the Ethics committee of the Christian Medical College and 
Hospital, Vellore (Annexure I). Written informed consent was obtained 
from close relatives of all subjects before participation in the trial 
(Annexure II). 
 
Setting 
Christian Medical College Hospital is a 2200 bedded tertiary care teaching 
hospital in South India. The Medical ICU is an 11 bedded facility where 
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patients from all three medicine units and Medicine related super specialty 
are admitted. 
 
Inclusion criteria 
All patients aged 14 years or older who presents to the emergency 
department following poison ingestion and receive gastric lavage. 
 
 
Exclusion criteria 
The study excluded subjects who met the following criteria. 
 Known hypersensitivity to Beta-lactam antibiotics. 
 Any evidence of pulmonary infection at the time of recruitment as 
suggested by clinical criteria below. 
 Any subject who is receiving antibiotics for any other established 
infection at the time of recruitment. 
 Any subject who has received treatment with any antibiotic within 
the past 4 days 
 Pregnant women. 
 Patients who had gastric lavage and activated charcoal elsewhere 
prior to admission were also excluded. 
 Patients who ingested non toxic doses of drugs and hence 
expected to be discharged within 24 hours of admission. 
 Refusal by the next of kin to participate in the clinical trial. 
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Intervention 
Recruited patients were randomly allocated to receive prophylactic 
antibiotics or an identical placebo. Interventions given at the time of 
recruitment are described below. Randomization was done by Biostatistics 
department. Simple randomization using random tables was the method 
used. The randomization codes were conveyed to the pharmacy unit in a 
sealed envelope. The study drugs and corresponding placebos were 
visibly indistinguishable and were prepared by independent pharmacists of 
the Clinical Pharmacology department of the Christian Medical College 
Hospital, Vellore. They were labeled with an identification number, which 
was noted in the patients’ chart as well as the data abstraction sheet to 
allow for unblinding after completion of the study. Drugs/ placebo were 
then handed over to the emergency unit nurses who remained blinded to 
the trial. Primary investigator assessed the patient for eligibility criteria and 
the allocation was concealed. 
Antibiotic prophylaxis group : Patients randomized to the antibiotic 
group received a combination regimen of three doses of crystalline 
penicillin intravenously at a strength and dose of 20 lakh units given every 
four hours  plus 
Single dose of intravenously administered Levofloxacin 500 mg 
Control group: These subjects did not receive any prophylactic 
antibiotics. They received identical appearing intravenous placebo 
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There is no literature on the dose and duration of antibiotic prophylaxis in 
this group of patients(i.e poisoned subjects who receive gastric lavage) 
This prophylactic regimen was considered akin to infective endocarditis 
regimen and hence short duration of treatment was determined. Prior to 
randomization, eligible subjects also received a test dose of crystalline 
penicillin and those who tested positive were excluded from the trial. 
All study medications were given immediately after randomization and 
after chest radiographs and baseline blood samples were taken. In 
addition all patients received additional supportive therapy and antidotes 
wherever indicated.  
 
All deaths and adverse effects were monitored by a data monitoring 
committee. The pharmacy and the data monitoring committee were 
allowed to break the code in the event of a serious adverse event 
attributed to the study drug or a serious infection for which this knowledge 
was deemed essential to guide antibacterial therapy. Unblinding was not 
offered routinely in the event of a respiratory infection. 
 
Data and specimen collection 
All data were noted on standardized documentation sheets and 
exclusively collected by the primary investigator (AnnexureIII). The 
primary investigator was not involved in patient care or in diagnostic or 
therapeutic decisions. Data recorded on admission included demographic 
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and diagnostic information on the patients, interventions, calculations of 
APACHE II scores. The patients were monitored daily for the presence of 
pulmonary infections, organ failures and other complications according to 
the specified definitions. On enrollment, chest radiographs, blood counts 
and blood chemistries were taken by personnel blinded to the study. Blood 
counts and chest radiographs were repeated every 48 hours. Additional 
samples and radiographs were collected if considered necessary by the 
treating physician. Whenever there was a suspicion of infection, samples 
were obtained for microbiologic cultures, including endotracheal aspirate 
and at least two separate blood specimens.  
 
END POINTS 
Primary outcome was the occurrence of pneumonia as defined by 
objective criteria. Objective criterion for pneumonia was defined according 
to the criteria given by other investigators4,8,19,47 and based on the CDC 
criteria for pneumonia.69 
Two or more serial chest radiographs with at least one of the following: 
 New or progressive and persistent infiltrate  
 Consolidation 
 Cavitation          
And, at least one of the following: 
  Fever (> 38°C or >100.4°F) with no other recognize d cause 
  Leukopenia (< 4,000 WBC/mm3) or leukocytosis (>12,000 
WBC/mm3) 
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 More than 10% of band forms 
 
 
And at least two of the following: 
• New onset of purulent sputum, or change in character of sputum, or 
increased respiratory secretions, or increased suctioning requirements 
• New onset or worsening cough, or dyspnea, or tachypnea 
• Rales or bronchial breath sounds 
• Worsening gas exchange (e.g., oxygen desaturations [e.g., PaO2/FiO2 < 
240], increased oxygen requirements, or increased ventilation demand) 
OR a clinical pulmonary infection score more than 6. (Annexure IV) 
Purulent sputum is defined as secretions from the lungs, bronchi, or 
trachea that contain >25 neutrophils and <10 squamous epithelial cells per 
low power field (x100). 
Change in character of sputum refers to the color, consistency, odor, 
and quantity. 
 
For the purpose of study, pneumonia occurring within 4 days of 
hospitalization was assumed to be due to aspiration occurring at the time 
of decontamination. Pneumonia occurring after four days of intubation was 
labeled as late onset ventilator associated pneumonia. 
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 Secondary outcomes 
Secondary outcome measures were mortality duration of hospital stay, 
medical intensive care unit stay and mechanical ventilation. 
 
Ethical Issues 
1. There is clinical equipoise in this area with no studies reporting a benefit 
with treatment. 
2. Only a short course of antibiotics used to minimize antibiotic resistance 
as the optimal dose and duration of prophylaxis were not known due to 
paucity of data in the literature. 
3. Project was submitted to the ethics committee of Christian Medical 
College and Hospital, Vellore and approval was obtained (Annexure I). 
4. Informed consent was obtained for all patients in the study from next of 
kin after explaining the details of the trial. 
 
Sample size calculation and Power  
The study was designed to test the hypothesis that prophylactic antibiotics   
given intravenously would reduce the incidence of pneumonia in the 
population mentioned above. An audit of the previous ten months data on 
204 poisoned subjects showed a pneumonia incidence of about 35% in 
poisoning subjects. This audit was necessary as there was a wide 
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variation in the incidence of pneumonia reported in poisoned subjects (4 to 
50%.in various studies).7,8,9 
 
Assuming an incidence of pneumonia of 35% in the control group, a  
sample size of 51 in each arm was calculated to be necessary to show a 
25% reduction in the incidence of pneumonia in the antibiotic treated  
group assuming 5% level of significance [alpha = 0.05] and a power [1-
beta] of 80%, by two sided test.  
 
Stastical analysis 
Stata 8 was used for sample size calculations and power analysis. SPSS 
version 11 and EPIinfo 2002 were used for the statistical analysis. The 
continuous variables were expressed as mean + standard deviation and 
categorical variables were expressed as counts (percentages) unless 
stated otherwise. The endpoints were predefined and analyzed on an 
intention to treat basis. Continuous variables were analyzed using 
independent t test when the distribution of the variables were normal and 
by Mann-Whitney U test when the distribution was not normal. Chi-square 
and Fisher’s exact test were used wherever appropriate for analysis of 
categorical variables. The risk ratios and the number needed to treat were 
also calculated wherever appropriate. 
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                           RESULTS 
 
 
 
I. BASELINE CHARACTERISTICS 
 
 
Between October 31st 2005 and August 1st 2006, a total of 209 patients 
were admitted to the hospital with a diagnosis of poisoning / overdose. 
Hundred and four patients who fulfilled criteria for inclusion were enrolled 
into the study (figure 5). Of the 104 patients, 53 were randomized to the 
antibiotic group and the remaining 51 to the placebo group. The reasons 
for exclusions are summarized in the chart (figure 5). The commonest 
reason for exclusion was non toxic doses of drug overdoses. No patients 
were lost to follow up. The baseline characteristics of the study population 
were found to be comparable and are shown in tables 5-7.   
 
 
 
Prophylactic 
antibiotic  
group 
 
N=53 
Placebo 
group 
 
 
N=51 
p value 
Age      mean + SD (yrs.) 28 +  6 31 +15 0.843 
Males [ % ] 34 [ 64.2] 25 [49] 0.119 
Diabetes  2 [3.8] 2 [3.9 ] 1.00 
Hypertension 3 [5.7 ] 0 0.243 
Smoking habit 10 [18.9 ] 7 [13.7] 0.478 
Alcohol intake 15 [28.3] 7 [13.7 ] 0.069 
Chronic obstructive airway disease 0 2 [3.9] 0.238 
Table.5. Demographics 
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Figure 5.  Trial profile 
 
 
 
 
 
Excluded (n= 105) 
Corrosive poisoning ( n= 15 ) 
Hydrocarbon ( n= 10) 
Received antibiotics 
elsewhere (n= 4) 
Delayed presentation [more 
than 4 hours] (n= 14) 
Gastric decontamination 
elsewhere (n= 16) 
Refused to participate (n=8) 
Penicillin hypersensitivity (n= 
6) 
Non toxic doses of drug 
overdoses (n= 32) 
Analyzed (n= 53) 
 
Excluded from analysis - none 
 
Lost to follow-up- none 
Discontinued intervention- none 
     
Allocated to Antibiotic group 
(n= 53 ) 
Received allocated intervention 
(n= 53) 
Lost to follow-up - none 
Discontinued intervention- none 
Allocated to placebo group    
(n=51)  
Received allocated intervention 
(n=51) 
   
Analyzed (n= 51) 
 
Excluded from analysis - none 
Allocation 
Analysis 
Follow-Up 
Enrollment 
 Randomized 
Assessed for eligibility 
               (n= 209) 
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Prophylactic 
antibiotic  
group 
N=53 
Placebo 
group 
 
N=51 
p value 
Time to gastric lavage from poison 
ingestion [in minutes] 
149 + 63  160 + 64 0.350 
Systolic blood pressure 
At admission 
122 + 17 122 + 21 0.736 
Heart rate at admission 97 + 17 100 + 19 0.538 
Saturation 95 + 8 92 + 15 0.917 
GCS score 13 + 3 13 + 4 0.668 
Intubation 17 [32.1] 15 [29.4] 0.769 
Place of intubation 
     Emergency room 
     Ward 
     Medical ICU 
 
10 
6 
1 
 
13 
2 
0 
 
 
Time to intubation in hours from 
admission 
8 + 14 7+ 15  0.883 
Admission 
Ward 
MICU 
 
42 
11 
 
40 
11 
 
0.919 
APACHE II score 8 + 5 9 + 6 0.157 
Enteral feeding 38 34 0.578 
Stress ulcer prophylaxis 49 46 0.739 
 
Table6. Clinical Characteristics at admission 
 
 
Prophylactic 
antibiotic  
group 
N=53 
Placebo 
group 
 
N=51 
p value 
Hemoglobin  mean 14.3 + 2.4 14 + 2.2 0.199 
Total WBC count  mean  12454 + 4321 12684 + 
5125 
0871 
S.creatinine  mean  0.9 + 0.2 1.0 +0.5 0.258 
RBS       mean  123 + 40 130 + 37 0.106 
Sodium         mean  140 + 3.8 140 + 4.2 0.725 
Potassium   mean  3.5 + 0.5 3.6 + 0.5 0.715 
Bicarbonate  mean  20 + 3 20+ 3 0.547 
Liver dysfunction  1 2 0.614 
Pseudocholinesterase in OP 1442 + 1765 1025 + 1445 0.417 
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Table.7 Laboratory characteristics at admission 
The mean age of the study population was 28 [range 16-70] in the 
prophylactic antibiotic group and 31 [range 14-70] in the placebo group. 
Majority of the patients were in the 21-30 age group (figure 6). Among the 
104 patients included in the study, 59 (56.7%) were males and 45 (43.3 
%) were females (figure7). All cases of the poisoning were due to 
deliberate self harm. 
 
 
 
 
Prophylactic 
antibiotic  group 
Placebo group 
Poison type 53 51 
Insecticides 
organophosphate 
32 
23 
29 
18 
organocarbamate 1 1 
chlorinated hydrocarbon 1 2 
pyrethroid 7 8 
Plant poisons 
oduvanthalai 
1 
1 
7 
3 
oleander   4 
Sedatives and 
antipsychotics 
tricyclic 
4 
 
2 
3  
barbiturates 1 1 
benzodiazepines 1 1 
antipsychotic   1 
Rodenticides 3 1 
Others 
non ionic surfactant 
13  11 
1 
unknown 5 4 
other plant fertiliser 2 2 
theophylline 1   
multiple drug overdosage 4 1 
paracetamol   1 
phenytoin   1 
antidiabetic 1 1 
Severity of OP poisoning 
  
Mild 7 9 
Moderate 5 1 
Severe 10 9 
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Table 8 Poison type and severity 
Age distribution
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Figure. 6 Age distribution of the study patients. 
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Organophosphates were the most common compound involved in 
poisoning,39.4% of all poisonous compounds. (figure.8) Severity of 
organophosphate poisoning was evaluated using Namba’s criteria 
(Annexure IV)  
 
 
Male
57.6%
Female 
43.3% 
Male  Female
Figure 7  Sex distribution 
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Frequency
41
2
3
15
4
4
2
2
2
1
1
2
1
4
1
9
4
1
5
organophosphate
organocarbamate
chlorinated hydrocarbon
pyrethroid
oduvanthalai
oleander
tricyclic
barbiturates
benzodiazepines
paracetamol
phenytoin
antidiabetic
antipsychotic
rat poison
non ionic surfactant
unknown
other plant fertiliser
theophylline
multiple drug overdosage
 
Figure.8 Frequency of poison consumed 
II. PRIMARY OUTCOME 
 
Overall, 11.5 % (n= 12) of the study population fulfilled the clinical criteria 
for pneumonia.  Three belonged to the prophylactic antibiotic group and 9 
belonged to the control or placebo group, p= 0.056. (figure.9). The risk 
ratio for patients receiving prophylactic antibiotics compared to patients 
receiving placebo was 0.32 [95% confidence interval, CI = 0.09 -1.12] 
(table 9).  Although the risk reduction in terms of aspiration pneumonia 
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with antibiotics was 68%; this did not reach statistical significance. All 
cases of pneumonia occurred in the mechanical ventilated group.  
 
antibiotic group
placebo group
pneumonia
3
9
0
2
4
6
8
10
pneumonia
 
Figure   9      Pneumonia rates in antibiotic and placebo group 
 
 
Only one patient had pneumonia occurring after four days of intubation. 
(late onset pneumonia).52 
 
Outcomes Antibiotic 
group 
Placebo 
group 
RR 95% CI P value 
Primary outcome 
[Pneumonia all 
patients] 
3  9 0.32 0.09 -1.12 0.056 
Mortality in all patients                   5                   5 0.96 0.30-3.13 1.00 
  
Table. 9 Primary outcome and mortality  
Number 
of patients 
p = 0.056 
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SECONDARY OUTCOMES 
 
 There was no statistically significant difference between the 
antibiotic and placebo groups for all cause mortality (table 9), 
duration of hospital stay, MICU stay and mechanical ventilation.  
(table10) 
 
A. Mortality 
A total of ten patients enrolled in the study died.  Both the prophylactic and 
control groups had equal number of deaths (5 each) (table9). Of the ten 
subjects who died, five had died due to pneumonia and sepsis, two died 
due to hypoxia related to tube block and other three due to effects of 
severity of poisoning. Five out of 12 patients who developed pulmonary 
infection died compared with five out of 92 patients without pulmonary 
infection. [p value=0.001] 
 
 
B. Duration of hospital stay 
Total duration of hospital stay was 6 + 6 versus 6 + 5 days for the 
prophylactic antibiotic and placebo groups respectively.  (p=0.437). 
When analyzing patients who developed pneumonia and those who 
did not, total hospital stay was 13 + 8 and 5 + 5 respectively (p=0.000) 
which was statistically significant. 
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C. Duration of intensive care unit stay 
Total duration of ICU stay was 9 + 5 versus 8 + 6 days for the 
prophylactic antibiotic and placebo groups respectively.  (p=0.489) 
 
 
Antibiotic group Placebo group P value 
Duration of hospital stay ( 
in days) 
6 + 6 6 + 6 0.437 
Duration of ICU stay( in 
days) 
9 + 5 8 + 6 0.489 
Table. 10  secondary outcomes  
 
 
 
D. Adverse drug reactions 
 
                   No adverse drug reactions were recognized in patients 
receiving either intervention. 
 
 
E. Microbiology 
 
The isolates from the 12 patients who developed pneumonia is shown in 
the table. Both groups had equal number of gram positive organisms.  
There was no statistical difference between the two groups for the gram 
negative organisms [p value=1.00] (table11) 
 
Micro organism Number of Antibiotic group Placebo group 
 48
isolates (n=3) (n= 9) 
Staphylococcus 
aureus 
2 0 2 
Alpha hemolytic 
streptococci 
2 1 1 
Staphylococcus 
Epidermidis 
2 1 1 
Morganella 1 0 1 
Pseudomonas 
aeruginosa 
1 0 1 
Klebsiella sp 2 1 1 
E. Coli 1 0 1 
Other non 
fermenting gram 
negative bacteria 
3 1 2 
Total 14 4 10 
 
Table 11 Isolated microorganisms in the 12 episodes of pulmonary infection 
 
 
 
 
F. Treatment of Pneumonia 
 
Empiric antibiotics were begun and were adjusted according to the culture 
and sensitivity results. Antibiotics that were given were cefepime, 
augmentin, aminoglycosides and metronidazole. These antibiotics were 
given as monotherapy or in combination. 
 
 
 
III. SUB GROUP ANALYSIS 
   
Since all pneumonias occurred in the ventilated population, a post hoc 
subgroup analysis was done for that group. The results are as follows. 
 
A. Incidence of pneumonia in Ventilated patients 
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    Out of 32 ventilated patients, 12 developed pneumonia, 3 in the 
antibiotic group and 9 in the placebo group. p value= 0.014. Distribution of 
ventilated patients among the two groups is shown in table12. The results 
were statistically significant. The calculated risk ratio for patients receiving 
prophylactic antibiotics compared to patients receiving placebo was 0.29 
[95% confidence interval, CI=0.10 -0.89]. Absolute risk reduction was 43 
giving a number needed to treat of 2.3. (table13) 
 
    Total 
 Antibiotic group Placebo 
              group 
 
 
  
ventilated 17 15 32 
Not ventilated 36 36 72 
Total  53 51 104 
 
Table.12 Distribution of ventilated patients among the two groups 
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Figure 10 Pneumonia rates among ventilated patients 
 
 
 
 
Outcomes Antibiotic 
group 
Placebo 
group 
RR 95% CI P value 
Pneumonia in 
ventilated patients 
[Post hoc subgroup 
analysis] 
3 9 0.29 0.10-0.89 0.014 
Mortality in vetilated 
patients [Post hoc 
subgroup analysis] 
5 5 0.88 0.32-2.46 1.00 
Table.13 Pneumonia incidence  and mortality  in ventilated population  
 
Duration of Mechanical ventilation, hospital and ICU stay in 
ventilated population 
Number 
of 
patients 
p = 0.014 
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There was no statistically significant difference between the two groups for 
the duration of mechanical ventilation. Total duration of mechanical 
ventilation (mean + SD) for the ventilated poisoned subjects were 7 + 6 
versus 7 + 5 days for the prophylactic antibiotic and placebo groups 
respectively.  (p=0.856) (table14). Duration of mechanical ventilation prior 
to the development of pulmonary infection was 2.7 + 2.9 and 2.2 + 1 days 
for the antibiotic prophylactic and control groups respectively (p=0.631). 
There was no statistically significant difference between the two groups for 
the duration of hospital stay and intensive care unit stay (table15).   
 
 
Antibiotic group Placebo group P value 
Duration of mechanical 
ventilation ( in days) 
7 + 6 7 + 5 0.856 
 
Table.14 Duration of mechanical ventilation 
 
 
Antibiotic group Placebo group P value 
Duration of hospital stay 11+ 9 12 + 7 0.677 
Duration of ICU stay 9 + 5 9 + 6 0.970 
 
Table.15 Duration of hospital stay and icu stay for ventilated subjects  
 
Kaplan Meier curve for patients remaining free of pneumonia in ventilated 
patients is shown in the figure 11. Among the ventilated patients, 
significantly fewer patients who received antibiotics acquired infections. 
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Figure 11 Kaplan Meier curve for patients remaining free of pneumonia in 
ventilated patients for the two groups 
 
Sepsis in ventilated group 
A total of 9 patients fulfilled the standard criteria for sepsis (Annexure V) in 
the ventilated population. Two belonged to the antibiotic group and seven 
belonged to the placebo group. (p=0.049) 
 
 
Risk factors for developing pneumonia 
Univariate analysis identified male sex and GCS <8 as predictors of 
pneumonia in the entire cohort of poisoned subjects.  Multivariate analysis 
Days after randomization 
P= .0163 
Log rank Antibiotic 
group 
Placebo 
group 
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could not be done because number of patients with pneumonia was too 
small.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                              DISCUSSION 
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                      This study, a prospective randomized double blind placebo 
control trial of short course prophylactic antibiotics (three doses of 
crystalline penicillin and single dose of Levofloxacin),  suggested a trend 
towards a reduction of incidence of aspiration pneumonia with antibiotic 
prophylaxis in patients presenting with poisoning (p=0.056). It is important 
however, to note that all pneumonias occurred in mechanically ventilated 
patients.  This observation could reflect the fact that the sicker, critically ill 
patient is particularly at risk for aspiration and its consequences. A post 
hoc analysis in this subgroup of mechanically ventilated patients showed a 
relative risk reduction of 71% (95% confidence interval, CI 0.10-0.89) and 
an absolute risk reduction of 43% with antibiotics compared to the 
placebo. Thus, the number of patients who needed to be treated (NNT) to 
avoid one episode of pneumonia in poisoned subjects needing ventilatory 
support was an impressive 2.3 patients.  
  
                  Our findings assume importance given that this is the first 
randomized double blind placebo controlled trial of short course antibiotic 
prophylaxis in patients presenting with poisoning.                                            
 
             The impact of short courses of systemic antibiotic prophylaxis in 
reducing the incidence of pneumonia has been studied in other clinical 
situations (table16). In a randomized controlled trial by Sirvent et al13, 
short term antibiotic prophylaxis (two single cefuroxime doses 1500 mg 
each 12 hour apart after intubation was demonstrated to significantly 
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reduce the occurrence of pneumonia in patients with coma. The 
occurrence of pneumonia was 50% in the control group and 24% in the 
cefuroxime group (a 52% relative risk reduction). When considering early 
onset pneumonia which accounted for 70% of all pneumonias, the relative 
risk reduction was 56% (36% controls, 16% cefuroxime group). The cohort 
in the above study consisted of previously well individuals who required 
mechanical ventilation following head injury or stroke and is comparable in 
some ways to our patient population. 
 
               In another single centre prospective open study14 a three day 
prophylaxis with ampicillin –sulbactam [3gm every 6 hours for three days] 
significantly reduced the occurrence of early onset pneumonia in critically 
ill comatose mechanically ventilated patients. The risk reduction for 
pneumonia again was impressive at 64 % and similar to that obtained for 
the mechanical ventilated subjects in our study. The open label study 
design and small sample size (19 in each group) were considered to be 
the major limitations of that study. 
                Prophylactic antibiotics, on the other hand, may not be without 
adverse effects. Ewig et al70 in a prospective observational study showed 
that prolonged found that prolonged antibiotic prophylaxis independently 
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Study Antibiotic 
regimen and 
duration 
Type of patients Number of 
patients in the 
study 
Number of 
patients in each 
group 
[placebo/ 
antibiotic] 
Pneumonia 
incidence in the 
control / 
standard 
therapy group 
Pneumonia 
incidence in 
the antibiotic 
group 
Relative risk 
reduction 
P value 
Sirvent  
et al 13 
Two single doses 
of cefuroxime 
1500mg each12 
hours apart 
individuals who 
required mechanical 
ventilation following 
head injury or stroke 
100 50 / 50 25 / 50 12 / 50 52% .007 
Acquarolo et al14 ampicillin–
sulbactam 3gm 
every 6 hours for 3 
days 
critically ill comatose 
mechanically 
ventilated patients 
38 19 / 19 11 / 19 4 / 19 64 % .022 
Mechanical 
ventilated patients 
in our study 
Three doses of 
crystalline penicillin 
(20 lakh units) four 
hours apart and a 
single dose of 
levofloxacin (500 
mg) 
Poisoned subjects 
who require 
mechanical ventilation 
32ventilated 
patients 
15 / 17 9 / 15 3 / 17 71% 0.014 
 
 
Table16 Comparison of our study with other studies on short course prophylactic antibiotics in critically ill patients 
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 predicted late onset pneumonia. The mean duration of treatment was 5 
days in that study. In another study, Hoth et al71 in a retrospective 
observational study found that for patients receiving prolonged 
prophylactic antibiotics (mean, 8 days) the first pneumonia was diagnosed 
later, the causative organisms were more likely to be resistant or gram-
negative bacteria, and the occurrence of antibiotic complications was two 
times greater than for patients who did not receive antibiotic prophylaxis.  
 
                         Several investigators have used combinations of topical 
and parenteral antibiotics for selective digestive decontamination in ICU 
with a view to reducing the incidence of nosocomial pneumonia. Liberati et 
al71 in a recent meta-analysis of randomized control trials comparing 
different forms of antibiotic prophylaxis (topical oral non-absorbable, 
systemic, combined topical and systemic) found a strong reduction in 
respiratory tract infection and mortality when a combination of topical and 
systemic antibiotics were used. A recent large randomized control trial73 
comparing critically ill medical patients receiving oral topical non-absorbed 
antibiotics combined with an initial 4-day course of intravenous cefotaxime 
with controls receiving standard treatment also found decreased ICU and 
hospital mortality in patients receiving antibiotic prophylaxis. The studies 
support the use of prophylactic antibiotics in the prevention of nosocomial 
infections, particularly pneumonias. A major difference however between 
these studies and our current study was the clinical situation (poisoning) 
as well as the duration of antibiotic prophylaxis (short duration). The total 
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cost of the prophylactic antibiotic regimen used in our study was about 
Rs.100 \- per patient, a likely cost saving approach if one was to consider 
the costs of treatment of one episode of pneumonia.  
 
                      No statistically significant differences were observed 
(although there was a favorable trend) with regard to primary outcome 
when comparing the study population and the control group in our study. 
This lack of difference could be explained by several reasons including 
sample size limitations.  Prior to the start of the study, an audit of the 
previous ten months showed a pneumonia incidence of about 35% in 
poisoning subjects. In our prospective study, the pneumonia rate in the 
control group was only 17.6%. This decrease in the pneumonia incidence 
in the control group could have affected the effective sample size and 
power of the study. We speculated the decrease in pneumonia rates to be 
due to the following reasons. The population in the audit study prior to the 
clinical trial also included subjects who had received gastric lavage 
elsewhere and this may have contributed to the higher incidence. Our 
study excluded patients who had received gastric decontamination 
elsewhere. In a recent observational study12 in Sri Lanka, an improperly 
conducted gastric lavage without adherence to the recommended 
methods was found to carry a high risk of aspiration and other 
complications including death. This study done also noted that several 
hospitals in the South East Asian region were not performing lavage as 
recommended and that frequent and serious complications frequently 
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resulted. In our study, recommended methods (Annexure VI) for lavage 
was strictly adhered to by the emergency room nurses, who were trained 
alike. This could have resulted in a decreased incidence of pneumonia in 
the control group in our study. 
 
                 No differences were observed with regard to secondary 
outcomes in our study. The lack of difference in secondary outcomes 
when comparing the two groups could be explained by factors other than 
pneumonia that accounted for morbidity and mortality. Of the five patients 
who died in the antibiotic group, only one (20%) died due to pneumonia, 
whereas of the five deaths in control group, four (80%) had died due to 
pneumonia. The remaining four deaths in the antibiotic group were due to 
other factors such as hypoxia related to tube block in two patients.  As 
mentioned earlier when we compared patients with pneumonia with those 
who did not develop it, there was a reduction in total duration of hospital 
stay. 
 
               An important question in any prophylactic antibiotic trial that 
needs to be addressed is whether the prophylaxis may increase the 
emergence of multidrug resistant bacteria and adversely affect the 
outcome. In this present trial, both the control and placebo group had 
nearly equal number of gram positive bacteria isolated. Control group had 
slightly more gram negative bacteria and non fermenting gram negative 
rods. None of the organisms isolated in the antibiotic group was multidrug 
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resistant. This justifies the use of Levofloxacin in our trial to cover gram 
negative bacteria.  
 
                 This study answers certain questions and leaves us with 
several unanswered questions. In our study, prophylactic regimen was 
intended to give maximum protection during the initial 12 hours following 
hospitalization. Whether a protective effect against is provided by a longer 
duration of prophylaxis of 48- 72 hours needs to be studied. Again the role 
for prophylaxis in unintubated non mechanical ventilated poisoning 
patients needs to be clarified.  Due to difficulties in doing anaerobic culture 
and financial constraints, anaerobic cultures were not done as a part of 
our study. Also we did not do a formal cost effective analysis in the 
ventilated patients. Whether the prophylactic antibiotic therapy modifies 
the cost of treatment, hospital stay and indirect costs needs to be 
addressed. 
 
The major implications of our results could be the following. 
 
A. From the demographic profile and baseline characteristics of our study, 
poisoning appears to be a major problem in the younger age groups 
especially in males. Highly toxic compounds such as organophosphates 
are easily available and often are common household items. Policies such 
as minimum pesticide list should be made to restrict the availability of such 
highly toxic agents. Steps may be taken to prevent poisoning and 
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repeated suicidal attempts which in turn will reduce consequent morbidity 
and mortality associated with it. 
 
B.  Overall, there was a trend to a reduction in the incidence of pneumonia 
in poisoned subjects randomized to the prophylactic antibiotic group. The 
significant reduction in the incidence rates of pneumonia in the subgroup 
analysis of mechanical ventilated patients has important implications. 
 
1) With the mortality and morbidity associated with pneumonia in 
ventilated subjects being high, any intervention that could reduce the 
incidence of pneumonia is worthy of study and consideration. The benefits 
of antibiotic prophylaxis in this subgroup of ventilated patients thus have 
clinical as well as financial implications.  
 
2) A very short course antibiotic prophylaxis of three doses of penicillin 
and a single dose of Levofloxacin may be less likely to decontaminate the 
gut and favor the colonization of more pathogenic bacteria, although this 
was not looked at in this study 
 
C. This study has shown that patients who developed pneumonia had 
significantly increased mortality rates and duration of hospitalization.  
Hence measures to reduce pneumonia are of importance.  
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                             Limitations  
The major limitations in our study included the following. 
1. Sample size limitations since the end point of our study was the 
reduction of the incidence of pneumonia. 
2. Power of the study could have been affected since the pneumonia rate 
in the control group was less when compared to that at the beginning of 
the study. In fact, the recalculated power using incidence rates in the 
present study was 70%. A much larger trial with about 103 patients in 
each arm would be needed to demonstrate a benefit using incidence rates 
in the present study, assuming an Alpha error of 5% and a power of 80% 
by a one-tailed test. 
3. Anaerobic cultures were not routinely done due to difficulties in 
sampling and cost constraints. 
4. It was clinically impossible to differentiate between aspiration and early 
onset ventilator associated pneumonia in our study. The incidence of late 
onset pneumonia was small suggesting that aspiration at the time of 
poisoning or during gastric lavage at least predisposed to the development 
of early onset pneumonia.  
 
Conflicts of interest: None 
Financial disclosure: This study was done with the help of the generous 
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Conclusions 
 
                   In summary, the present study demonstrates that the 
administration of a combination of three doses of intravenously 
administered crystalline penicillin and a single dose of Levofloxacin 
resulted in a trend towards a reduction in the incidence of pneumonia in 
poisoned patients randomized to the prophylactic antibiotic group.   
 
                   Antibiotic prophylaxis is probably an effective prophylactic 
strategy for the prevention of pneumonia in mechanically ventilated 
poisoned subjects although the benefit did not reach statistical 
significance in the whole cohort of poisoned patients. 
 
                  These observations justify the conduct of a larger prospective 
study to evaluate the role of prophylactic antibiotics in poisoned patients. If 
such an intervention would reduce the morbidity and mortality, it would 
have great implications especially in our country where resources are 
limited. 
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ANNEXURE II 
INFORMED CONSENT DOCUMENT  
Study Title: Impact of short course prophylactic antibiotics in poisoning 
This information and consent form is meant for the closest kin of the patient 
This is a clinical trial, a type of research study.  Clinical trials include only people who 
choose to take part. Please take your time to make your decision about taking part.   
.  
1. Why is this study being done? 
Standard treatment for any poisoning presenting early to emergency department includes 
gastric lavage unless there are no contraindications. This procedure carries a high risk of 
aspiration and development of lower respiratory infection. 
The purpose of this study is to compare the effects, good and/or bad, of antibiotic 
[crystalline penicillin injection + levofloxacin] with [placebo] on the patient and to find out 
which is better in preventing lower respiratory tract infection. In this study, patient will get 
either the [drug/intervention] or the [placebo].  He/she will not get both. 
 Currently no antibiotics are given during gastric lavage by some medicine departments; 
whereas others prefer giving antibiotics. Drugs–penicillin and levofloxacin are common 
antibiotics given for the treatment of lower respiratory infection. They are not new agents 
being tested. 
 
3. How many people will take part in the study? 
A total of 102 people will take part in the study. 
 
4. What will happen if the patient take part in this research study?   
Patient will be “randomized” into one of the study groups described below. Randomization 
means that patient is put into a group by chance.  Neither you nor your doctor can choose 
the group patient will be in.  Patient will have an equal chance of being placed in any 
group. 
If patient is in group 1 (often called "Arm A") you will receive antibiotics -3 
intravenous injections of penicillin 4 hours apart and a single intravenous of 
levofloxacin in a 12 hour period. 
If patient is in group 2 (often called "Arm B’) you will receive a placebo. Placebos 
are inert substances i.e. they don’t have any effects (good or bad) on the body.  
 Study Plan  
 
Another way to find out what will happen to you during the study is to read the chart 
below.  Start reading at the top and read down the list, following the lines and arrows.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5. How long will patient be in the study? 
Till discharge from hospital/MICU 
6. Can patient stop being in the study? 
Yes.  You can decide to stop at any time.  
 
Study begins 
Agents used in this study 
 Injection crystalline penicillin three injections of 2 million units 4 hours 
apart for 12 hours + single dose of Levofloxacin 500mg intravenously and 
identical placebo 
Randomize  
(Patient will be in one Group or the other) 
Group 1.ANTIBIOTICS Group 2 .PLACEBO 
7. What side effects or risks can occur from being in the study?  
Side effects may occur while on the study.  Everyone taking part in the study will be 
watched carefully for any side effects.  However, we don’t know all the side effects that 
may happen.  Side effects may be mild or very serious. Many side effects go away soon 
after you stop taking the intervention. There also is a risk of death. 
  
8. Are there benefits to taking part in the study? 
While we hope intervention will be more useful in preventing, there is no proof of this yet. 
We do know that the information from this study will help us learn more about intervention 
as an agent in lower respiratory tract infection prevention 
 
9. Will patients’ medical information be kept private?  
 
We will do our best to make sure that the personal information in your medical record will 
be kept private.  However, we cannot guarantee total privacy.  Personal information may 
be given out if required by law.  If information from this study is published or presented at 
scientific meetings, name and other personal information will not be used.  
     
     Consent Document 
 
I, ----------------------------(name) closet kin of ---------------------(name) (relation) have been 
given a copy of all pages of this form.  I have read it or it has been explained to me in my 
own language.  I understand the information and have had my questions answered.  I 
agree for the patient to take part in this study. 
 
Closest kin’s signature ________________________________ 
 
Date _____________________________________ 
 
                                     
ANNEXURE III 
DATA ABSTRACTION FORM 
 
Title: Impact of short course prophylactic antibiotics in poisoning 
 
1. DEMOGRAPHIC DETAILS       Screening 
date: 
                                      
  Name:                                              Hospital number:                                   Medical Record Department 
number: 
 
  Age:                                                   Sex:          Unit: 
 
  Address:                                                  
 
 
 
 
 
 
 
 
 
      
2. RECRUITMENT No.                                                         INTERVENTION No. 
 
 
3. Past medical details 
 
Diabetes mellitus  Yes / No 
Hypertension Yes / No 
Smoking Yes / No 
Alcoholism Yes / No 
Asthma/Chronic obstructive pulmonary airway disease  Yes / No 
Past history of pulmonary tuberculosis Yes / No 
Ischemic heart disease Yes / No 
Congestive cardiac failure Yes / No 
 
 
4. Pre hospital details and details of poisonous substance ingested 
 
Poison / substance consumed: 
Amount consumed: 
Date and time of consumption: 
Reason for consumption: 
Was patient unconscious on discovery  Yes / No 
Other relevant history: 
 
 
 
5. Emergency room details 
Time to presentation to emergency room from ingestion [in hours]: 
Examination details at the time of admission 
 
 
  
 
 
INCLUSION CRITERIA MET               YES / NO         EXCLUSION CRITERIA MET YES / NO 
 
INFORMED CONSENT OBTAINED    YES / NO 
Blood pressure   Heart rate Respiratory rate      GCS     Saturation 
 In case of organophosphate poisoning : mild / moderate / severe 
 
 
 
Other salient examination findings 
 
 
Time to gastric lavage: 
Activated charcoal:    Yes / No             single / 
multidose 
Place of intubation:  ER/ ward / MICU 
Time to intubation in hours: 
        Lavage performed on intubated / un-intubated patient.       GCS at the time of lavage: 
 
 
6. Place of admission: ward/ MICU/ ward then MICU 
Date of admission:  Date of discharge: 
Early enteral feeding:  Yes / No 
NG tube insertion:        Yes / No 
Stress ulcer prophylaxis:   Yes / No 
Re-intubation  Yes / No     date: 
 
 
7. For organophosphate 
Dose and duration of atropine 
Intermediate syndrome  Yes / No                 Duration 
 
 
8. For patients admitted into medical ICU 
Time to MICU admission: 
APACHE II score at admission: 
SAPS score: 
TISS: 
Duration of MICU stay: 
Tracheostomy:  Yes / No  If yes, 
tracheostomy day 
 
 
9. Investigations 
 
At admission: Hemoglobin:  total WBC count:    differential 
WBC count 
Random blood sugar:     S. creatinine:              S.sodium:              S. potassium:                  
S.bicarbonate: 
 
Liver function tests: 
Pseudocholinesterase levels in organophosphate poisoning: 
Arterial blood gas 
DATE/DAY        
FiO2/PEEP        
pH        
Pco2        
Po2        
HCO3        
ABE        
SaO2        
 
 
 
WBC counts 
TC      
N      
L      
Ba      
E      
M      
BF      
META/MYELO      
 
Chest Radiograph:   Normal / abnormal  
Baseline 48 Hour 72 Hour 96 Hour 168 Hour 
     
 
Secretions Purulent   Yes / No 
Baseline 48 Hour 72 Hour 96 Hour 168 Hour 
     
 
Temperature 
Baseline 48 Hour 72 Hour 96 Hour 168 Hour 
     
 
Culture if done 
Antibiotic 
PATHOGEN 1       
PATHOGEN 2       
PATHOGEN 3       
PATHOGEN 4       
PATHOGEN 5       
 
 
10. Fulfilling criteria for pneumonia: Yes / No 
 
Time from lavage to pneumonia: 
If ventilated, time from ventilation to pneumonia: 
Time to resolution: 
Antibiotic used to treat pneumonia 
Number of antibiotic days:                                     
Duration of mechanical ventilation [days]:   CPIS scores in ventilated 
patients: 
 
11. MICU outcome:    alive / dead / discharged at request               Duration of ICU stay 
[days]: 
      Hospital outcome: alive / dead / discharged at request               Duration of hospital 
stay [days]: 
 
Any other nosocomial infection:     Sepsis  : Yes / No                          
Death                                            Yes / No           If yes cause of death                    
                  Time of death 
         
 
12. Adverse effects 
Adverse reaction noted: 
Any other complication of gastric lavage/charcoal noted: 
 
 
 
 
 
 
 
 
 
 
 
 
                                
                                        ANNEXURE IV 
           
 
 
                          
 
 
 
 
 
 
 
 
 
 
APACHE II SCORE 
The APACHE II score is a general measure of disease severity, based on current 
physiologic measurements, age and previous health condition. The score can help in the 
assessment of patients to determine the level and degree of diagnostic and therapeutic 
intervention. 
 Components: 
(1) acute physiology score (APS) 
(2) age points 
(3) chronic health points 
 Data collection: 
• The data for the acute physiology is collected during the initial 24 hour period after ICU 
admission. 
• The worst (most deranged) physiologic value is selected for grading. 
 Acute Physiology Score (APS)  
Parameter Finding Points 
rectal temp in C° >= 41 +4 
  39-40.9 +3 
  38.5-38.9 +1 
  36-38.4 0 
  34-35.9 +1 
  32-33.9 +2 
  30-31.9 +3 
  <= 29.9 +4 
mean arterial pressure mm Hg >= 160 +4 
  130-159 +3 
  110-129 +2 
  70-109 0 
  50-69 +2 
  <= 49 +4 
heart rate in beats/minute >= 180 +4 
  140-179 +3 
  110-139 +2 
  70-109 0 
  55-69 +2 
  40-54 +3 
  <= 39 +4 
respiratory rate in breaths/min >=50 +4 
  35-49 +3 
  25-34 +1 
  12-24 0 
  10-11 +1 
  6-9 +2 
  <= 5 +4 
oxygenation A-aDO2 >= 500 and FIO2 >= 0.5 +4 
  A-aDO2 350-499 and FIO2 >= 0.5 +3 
  A-aDO2 200-349 and FIO2 >= 0.5 +2 
  A-aDO2 < 200 and FIO2 >= 0.5 0 
  PaO2 > 70 and FIO2 < 0.5 0 
  PaO2 61-70 and FIO2 < 0.5 +1 
  PaO2 55-60 and FIO2 < 0.5 +3 
  PaO2 < 55 and FIO2 < 0.5 +4 
arterial pH >= 7.7 +4 
  7.6-7.69 +3 
  7.5-7.59 +1 
  7.33-7.49 0 
  7.25-7.32 +2 
  7.15-7.24 +3 
  < 7.15 +4 
serum sodium >= 180 +4 
  160-179 +3 
  155-159 +2 
  150-154 +1 
  130-149 0 
  120-129 +2 
  111-119 +3 
  <= 110 +4 
serum potassium >= 7.0 +4 
  6.0-6.9 +3 
  5.5-5.9 +1 
  3.5-5.4 0 
  3.0-3.4 +1 
  2.5-2.9 +2 
  < 2.5 +4 
serum creatinine in mg/dL >= 3.5 and not acute renal failure +4 
  2.0-3.4 and not acute renal failure +3 
  1.5-1.9 and not acute renal failure +2 
  0.6-1.4 and not acute renal failure 0 
  < 0.6 and not acute renal failure +2 
  >= 3.5 and acute renal failure +8 
  2.0-3.4 and acute renal failure +6 
  1.5-1.9 and acute renal failure +4 
  0.6-1.4 and acute renal failure 0 
  < 0.6 and acute renal failure +4 
hematocrit in percent >= 60 +4 
  50-59.9 +2 
  46-49.9 +1 
  30-45.9 0 
  20-29.9 +2 
  < 20 +4 
WBC count in thousands >= 40 +4 
  20-39.9 +2 
  15-19.9 +1 
  3-14.9 0 
  1-2.9 +2 
  < 1 +4 
Glasgow Coma Score   15 - (Glasgow Coma 
Score) 
 where: 
• The score for serum creatinine is doubled if the patient has acute renal failure. 
• mean arterial pressure =  ((systolic blood pressure) + (2 * (diastolic pressure))) / 3 
 If no blood gas data is available, then the serum bicarbonate can be used (I assume in 
place of the arterial pH):  
Parameter Finding Points 
serum bicarbonate in 
mmol/L 
>= 52.0 +4 
  41.0 − 51.9 +3 
  32.0 − 40.9 +1 
  22.0 − 31.9 0 
  18.0 − 21.9 +2 
  15.0 − 17.9 +3 
  < 15.0 +4 
 Age Points  
Age Points 
<= 44 0 
45-54 2 
55-64 3 
65-74 5 
>= 75 6 
 Chronic Health Points  
Operative Status Health Status Points 
nonoperative patient history of severe organ insufficiency OR 
immunocompromised 
5 
  no history of severe organ insufficiency 
AND immunocompetent 
0 
emergency postoperative 
patient 
history of severe organ insufficiency OR 
immunocompromised 
5 
  no history of severe organ insufficiency 
AND immunocompetent 
0 
elective postoperative 
patient 
history of severe organ insufficiency OR 
immunocompromised 
2 
  no history of severe organ insufficiency 
AND immunocompetent 
0 
 where:  
• organ insufficiency or immunocompromised state must have preceded the current 
admission 
• immunocompromised if: (1) receiving therapy reducing host defenses 
(immunosuppression, chemotherapy, radiation therapy, long term steroid use, high dose 
steroid therapy), or (2) has a disease severe enough to interfere with immune function 
such as malignant lymphoma, leukemia or AIDS 
• liver insufficiency if: (1) biopsy proven cirrhosis, (2) portal hypertension, (3) episodes of 
upper GI bleeding due to portal hypertension, (4) prior episodes of hepatic failure, 
coma or encephalopathy 
• cardiovascular insufficiency if: New York Heart Association Class IV 
• respiratory insufficiency if: (1) severe exercise restriction due to chronic restrictive, 
obstructive or vascular disease, (2) documented chronic hypoxia, hypercapnia, 
secondary polycythemia, severe pulmonary hypertension, (3) respirator dependency 
• renal insufficiency if: on chronic dialysis 
 APACHE II score = 
= (acute physiology score) + (age points) + (chronic health points) 
 Interpretation: 
• minimum score: 0 
• maximum score: 71 
• An increasing score is associated with an increasing risk of hospital death. 
  
 
Knaus WA, Draper EA, et al. APACHE II: A severity of disease classification system. 
Critical Care Medicine. 1985; 13:818-829. 
 
 
 
 
                                  ANNEXURE V 
 
Diagnostic Criteria for Sepsis  
Infection,a documented or suspected, and some of the following:b 
  
General variables 
•        Fever (core temperature >38.3°C) 
•        Hypothermia (core temperature <36°C) 
•        Heart rate >90 /min or >2 SD above the normal value for age 
•        Tachypnea 
•        Altered mental status 
•        Significant edema or positive fluid balance (>20 mL/kg over 24 hrs) 
•        Hyperglycemia (plasma glucose >120 mg/dL or 7.7 mmol/L) in the absence of 
diabetes 
Inflammatory variables 
•        Leukocytosis (WBC count >12,000 /mm3) 
•        Leukopenia (WBC count <4000 /mm3) 
•        Normal WBC count with >10% immature forms 
•        Plasma C-reactive protein >2 SD above the normal value 
•        Plasma procalcitonin >2 SD above the normal value 
Hemodynamic variables 
•        Arterial hypotensionb (SBP <90 mm Hg, MAP <70, or an SBP decrease >40 mm Hg 
in adults or <2 SD below normal for age) 
•        SvO2 >70%b 
•        Cardiac index (CI) >3.5 L.min-1.M-23 
Organ dysfunction variables 
•        Arterial hypoxemia (PaO2/FIO2 <300) 
•        Acute oliguria (urine output <0.5 mL.kg-1.hr-1 or 45 mmol/L for at least 2 hrs) 
•        Creatinine increase >0.5 mg/dL 
•        Coagulation abnormalities (INR >1.5 or aPTT >60 secs) 
•        Ileus (absent bowel sounds) 
•        Thrombocytopenia (platelet count <100,000 /mm3) 
•        Hyperbilirubinemia (plasma total bilirubin >4 mg/dL or 70 mmol/L) 
Tissue perfusion variables 
•        Hyperlactatemia (>1 mmol/L) 
•        Decreased capillary refill or mottling 
 
  
WBC, white blood cell; SBP, systolic blood pressure; MAP, mean arterial blood pressure; 
SvO2, mixed venous oxygen saturation; INR, international normalized ratio; aPTT, 
activated partial thromboplastin time. 
aInfection defined as a pathologic process induced by a microorganism;  
bSvO2 sat >70% is normal in children (normally, 75–80%), and CI 3.5–5.5 is normal in 
children; therefore, NEITHER should be used as signs of sepsis in newborns or children; 
cdiagnostic criteria for sepsis in the pediatric population are signs and symptoms of 
inflammation plus infection with hyper- or hypothermia (rectal temperature >38.5 or < 
35°C), tachycardia (may be absent in hypothermic patients), and at least one of the 
following indications of altered organ function: altered mental status, hypoxemia, increased 
serum lactate level, or bounding pulses. 
 
 
 
Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al.International Sepsis 
Definitions Conference.  Crit Care Med 2003;31:250-6. 
 
 
 
 
 
 
 
                                       Annexure vi 
 
Method for Gastric lavage  
The patient is placed in the left lateral decubitus position / head down position  (20 
tilt on the table). The length of tube to be inserted is measured and marked before 
insertion. A large bore 36–40 French or 30 English gauge tube (external diameter 
approximately 12–13.3 mm) should be used in adults; and 24–28 French gauge 
(diameter 7.8–9.3 mm) tube in children. The orogastric tube should be for single-
use only. The lavage tube should have a rounded end and be sufficiently firm to be 
passed into the stomach via the mouth, yet flexible enough not to cause any 
mucosal damage. The tube should be lubricated with a hydroxyethylcellulose jelly. 
 
Force should not be used to pass the tube, particularly if the patient is struggling. 
Once passed, the position of the tube should be checked either by air insufflation, 
while listening over the stomach, and/or by aspiration with pH testing of the 
aspirate. Traditionally, an aliquot of this sample has been retained for toxicological 
analysis though, except in the case of forensic examinations, the majority of 
laboratories now 
prefer blood and urine for analysis. . Lavage is carried out using small aliquots of 
liquid. In an adult, 200–300 mL (preferably warm 38C) fluid, such as normal saline 
(0.9%) or water, should be used. In a child, warm normal saline (0.9%) 10 mL/kg 
body weight of should be given. The volume of lavage fluid returned should 
approximate the amount of fluid administered. Water should be avoided in young 
children because of the risk of inducing hyponatremia and water intoxication. Small 
volumes are used to minimize the risk of gastric contents entering the duodenum 
during lavage, since the amount of fluid affects the rate of gastric emptying (50). 
Warm fluids avoid the risk of hypothermia in the very young and very old and those 
receiving large volumes of lavage fluid. Lavage should be continued until the 
recovered lavage solution is clear of particulate matter. It should be noted that a 
negative or poor lavage return does not rule out a significant ingestion.  
 
Contraindications 
• Loss of airway protective reflexes, such as in a patient with a depressed 
state of consciousness, unless intubated tracheally. 
• Ingestion of a corrosive substance such as a strong acid or alkali. 
• Ingestion of a hydrocarbon with high aspiration potential. 
• . Patients who are at risk of hemorrhage or gastrointestinal perforation due 
to pathology, recent surgery, or other medical condition such as a 
coagulopathy. 
 
 
 
 
 
Sno NAME HOSP.NO R.NU AGE SEX DM HTN SM ALC COPD POI T.ER BP HR SAT GCS SOP AC IT PIT TIT PLA ENT STP
1 Venkatesan S 839138c 2 23 1 2 2 2 1 2 1 160 140 120 99 15 1 1 1 1 1 1 1 1
2 Venkatesan 828021c 2 30 1 2 2 2 2 2 1 160 140 120 98 15 2 1 1 2 48 1 2 1
3 Jaganathan 862530c 2 63 1 2 2 1 1 2 4 30 150 92 98 9 N 1 1 1 0 1 1 2
4 Mani 856245c 1 50 1 2 2 1 1 2 4 200 110 110 65 7 N 1 1 1 0 1 2 1
5 Pitchandi 812060c 2 30 1 2 2 2 2 2 5 200 110 50 55 3 N 1 1 1 0 2 2 1
6 Govindaswamy 734772c 2 70 1 2 2 1 1 1 1 70 180 70 60 3 3 1 1 1 0 1 2 1
7 Sekar 850452c 1 25 1 2 2 1 1 2 1 120 120 80 96 15 3 1 1 2 7 1 2 1
8 Selvi 804265c 1 22 2 2 2 2 2 2 1 50 150 86 98 13 3 1 1 2 4 2 2 1
9 Latha 367563b 1 34 2 2 2 2 2 2 20 200 120 100 55 4 N 1 1 1 0 1 2 1
10 Deepalakshmi 832619c 1 21 2 2 2 2 2 2 20 220 110 80 92 8 N 1 1 1 0 2 2 1
11 Valarmathi 746597c 2 24 1 2 2 2 2 2 1 120 120 80 85 3 3 1 1 1 0 2 1 1
12 Eswaran 850182c 2 26 1 2 2 2 2 2 1 210 130 88 96 15 3 1 1 1 0 2 2 1
13 Venkatesan 846014c 1 30 1 2 2 2 1 2 1 30 110 126 80 7 3 1 1 1 0 2 2 1
14 Ramalingam 824766c 2 31 1 2 2 2 2 2 1 30 100 88 72 7 3 1 1 1 0 1 2 1
15 Balamurugan 745335c 1 21 1 2 2 2 2 2 1 105 110 80 96 4 3 1 1 1 0 2 1 1
16 Selvam 839091c 2 27 1 2 2 2 2 2 1 100 140 130 94 10 3 1 1 2 36 2 1 1
17 Sasikala 839240c 2 25 2 2 2 2 2 2 1 220 150 106 85 3 3 1 1 1 0 2 2 1
18 Gnanaprakasam 777440c 1 35 1 2 2 2 2 2 1 100 100 92 98 15 2 1 1 2 26 2 2 1
19 Shanmugham 852627c 1 23 1 2 2 2 2 2 1 200 130 80 94 15 3 1 1 2 48 1 1 1
20 Maran 747322c 2 23 1 2 2 2 2 2 1 210 100 140 96 15 1 1 1 1 15 2 1 1
21 Rajendiran 838502c 2 46 1 2 2 2 1 2 2 180 170 110 77 4 N 1 1 1 3 1 2 2
22 Sumitha 777503c 2 22 2 2 2 2 2 2 3 60 110 92 96 15 N 1 1 1 1 2 2 1
23 Mabu 824544c 1 23 2 2 2 2 2 2 4 140 90 92 98 15 N 1 2 N N 1 2 1
24 Ponmathy 746156c 1 27 2 2 2 2 2 2 20 240 100 120 99 3 N 1 1 1 4 2 2 1
25 Rajeswari 742317b 2 24 2 2 2 2 2 2 20 70 110 116 99 7 N 1 1 1 3 2 1 1
26 Pappa Rao 812075c 1 29 1 2 2 2 2 2 1 110 120 60 96 14 2 1 2 N N 1 2 1
27 Jhansi 789787c 2 18 2 2 2 2 2 2 1 240 90 150 97 12 3 1 2 N N 1 2 1
28 Moorthy 240942b 2 34 1 2 2 2 2 2 1 60 110 90 99 15 1 1 2 N N 1 2 1
29 Sunitha 815953c 1 14 2 2 2 2 2 2 1 30 130 118 99 15 1 1 2 N N 1 1 1
30 Devaraj 863381c 1 42 1 2 2 2 2 2 1 150 130 124 96 15 2 1 2 N N 1 1 1
31 Gunasekharan 758785c 1 30 1 2 2 2 1 2 1 200 150 110 99 15 1 1 2 N N 1 1 1
32 Babu 746498c 2 25 1 2 2 2 2 2 1 240 130 100 99 15 1 1 2 N N 1 2 1
33 Robinson 570640b 1 33 1 2 2 2 2 2 1 120 110 104 96 15 1 1 2 N N 1 1 1
34 Jaikumar 850450c 1 19 1 2 2 2 2 2 1 200 110 96 90 15 3 1 2 N N 1 1 1
35 Shanmugham 734423c 1 30 1 2 1 2 2 2 1 120 150 120 95 15 3 1 1 1 0 2 1 1
36 Srilatha 824529c 2 19 2 2 2 2 2 2 1 200 120 88 96 15 1 1 2 N N 2 2 1
37 Marimuthu 812155c 2 30 2 2 2 1 1 2 1 240 100 100 96 15 1 1 2 N N 1 1 1
38 Anushree 851691c 2 17 2 2 2 2 2 2 1 150 120 100 47 12 3 1 1 1 0 2 1 2
39 Bhanu 734289c 2 23 2 2 2 2 2 2 1 60 140 80 100 15 1 1 2 N N 1 2 1
40 Eswaraiah 832616c 1 25 1 2 2 2 2 2 1 240 140 110 97 15 1 1 2 N N 1 1 1
41 Ranganathan 871120c 1 40 2 2 2 2 2 2 1 45 110 84 98 15 1 1 2 N N 1 1 1
42 Chandran 828099c 1 45 1 2 2 1 1 2 1 90 110 110 97 15 1 1 2 N N 1 1 1
43 Mani 818727c 1 52 1 2 2 2 2 2 1 180 140 104 96 15 1 1 1 3 29 2 2 1
44 Vinila 812009c 1 20 2 2 2 2 2 2 1 210 130 130 96 15 1 1 2 N N 1 1 1
45 Suresh 744809c 2 22 1 2 2 2 2 2 1 100 110 106 20 15 1 1 2 N N 1 1 1
46 Anbazhagan 834195c 1 22 1 2 2 2 2 2 1 240 110 80 99 15 2 1 1 2 14 2 1 1
47 Sathya 734931c 1 18 1 2 2 2 2 2 1 210 110 110 96 12 3 1 1 1 0 2 1 1
48 Pachaiyappan 818898c 1 29 1 2 2 2 2 2 1 210 130 96 96 3 3 1 1 1 0 1 1 2
49 Shakthi 856053c 2 25 2 2 2 2 2 2 1 240 120 92 96 15 1 1 2 N N 1 1 2
50 Sathya N 254171b 1 34 1 1 2 2 1 2 1 140 120 88 96 15 2 1 1 2 0 1 2 2
51 Chakravarthy 789284c 1 25 1 2 2 1 1 2 1 180 120 100 100 13 3 1 2 N N 1 1 1
52 Ganesh 789624c 1 29 1 2 2 1 1 2 2 40 130 90 96 15 N 1 2 N N 1 1 1
53 Pushpa 804055c 2 32 2 2 2 2 2 2 3 120 120 110 99 15 N 1 2 N N 1 1 1
54 Hussaini Begum 870052c 1 18 2 2 2 2 2 2 3 120 120 80 96 15 N 1 2 N N 1 1 2
55 Vinoth 876240c 1 21 1 2 2 2 2 2 4 180 80 60 96 14 N 1 2 N N 1 2 1
56 Kumaran 804220c 1 23 1 2 2 2 2 2 4 120 120 90 96 15 N 1 2 N N 1 1 1
57 Suresh 818577c 2 17 1 2 2 2 2 2 4 210 140 130 99 9 N 1 2 N N 1 1 1
58 Radha 828045c 1 20 2 2 2 2 2 2 4 200 120 90 96 15 N 1 2 N N 1 1 1
59 Indira 828044c 2 33 2 2 2 2 2 2 4 200 130 104 96 15 N 1 2 N N 1 1 1
60 Ramesh 820146c 2 28 1 2 2 2 2 2 4 120 120 90 98 15 N 1 2 N N 1 1 1
61 Thulasi 822101c 2 37 2 2 2 2 2 2 4 210 100 92 86 14 N 1 2 N N 1 1 1
62 Jeyanthi 789483c 2 20 2 2 2 2 2 2 4 180 120 80 96 15 N 1 2 N N 1 1 1
63 Munisekar 838183c 2 18 1 2 2 2 2 2 4 60 130 130 99 15 N 1 2 N N 1 1 1
64 Jayashankar 846016c 1 23 1 2 2 2 2 2 4 50 130 110 100 15 N 1 2 N N 1 1 1
65 Arul J 876245c 2 38 1 2 2 1 1 2 4 180 90 112 98 13 N 1 2 N N 1 2 1
66 Ramamoorthy 733126c 2 65 1 2 2 1 2 2 5 200 110 70 99 15 N 1 2 N N 1 1 1
67 Nagabhooshanam 804344c 1 35 1 2 2 2 2 2 5 240 170 68 96 15 N 1 2 N N 1 1 1
68 Gopalakrishnan 850444c 2 23 1 2 2 2 2 2 5 210 140 106 96 15 N 1 2 N N 1 1 1
69 Vijayalakshmi 804340c 2 36 2 2 2 2 2 2 6 190 100 100 96 15 N 1 2 N N 1 1 1
70 Vinitha 838785c 2 14 2 2 2 2 2 2 6 180 110 100 99 15 N 1 2 N N 1 1 2
71 Janaki 863248c 2 60 2 1 2 2 2 2 6 210 130 104 99 15 N 1 2 N N 1 1 1
72 Birunda 824702c 2 25 2 2 2 2 2 2 6 220 100 96 96 15 N 1 2 N N 1 1 1
73 Kalpana 529238c 1 25 2 2 2 2 2 2 7 150 130 90 100 12 N 1 2 N N 1 1 1
74 Susila 592512b 1 37 2 2 1 2 2 2 7 60 160 68 99 14 N 1 1 1 2 2 2 1
75 Prakasam 789538c 1 34 1 2 2 2 1 2 8 215 130 100 98 15 N 1 2 N N 1 2 1
76 Poornima 686631b 2 15 2 2 2 2 2 2 8 90 100 80 97 14 N 1 2 N N 2 2 1
77 Ranganathan 832618c 1 53 1 2 2 2 2 2 9 120 130 72 98 11 N 1 2 N N 1 1 1
78 Ranganathan 832618c 2 53 1 2 2 2 2 2 9 180 130 80 90 11 3 1 2 N N 1 1 1
79 Kalavathy 794949c 2 37 2 2 2 2 2 1 10 240 120 80 99 15 N 1 2 N N 1 1 1
80 Sathya 826271c 2 19 2 2 2 2 2 2 11 220 120 88 96 15 N 1 2 N N 1 1 1
81 Nirmala 714567c 1 36 2 2 1 2 2 2 13 210 135 110 96 15 N 1 2 N N 1 1 2
82 Rashida 513306b 2 25 2 2 2 2 2 2 13 210 140 100 96 15 N 1 2 N N 1 1 1
83 Radhammal 395019b 2 70 2 2 2 2 2 2 14 180 130 80 96 15 N 1 2 N N 1 1 1
84 Vijay 665268a 2 18 1 2 2 1 2 2 15 60 110 110 100 14 N 1 2 N N 1 1 1
85 Kishore K 777458c 1 25 1 2 2 1 1 2 15 120 120 120 96 15 N 1 2 N N 1 1 1
86 Nathiya 834939c 1 17 2 2 2 2 2 2 15 60 110 90 96 15 N 1 2 N N 1 1 1
87 Alamelu 846488c 1 26 2 2 2 2 2 2 15 210 110 100 99 15 N 1 2 N N 1 1 1
88 Subashini 789399c 2 38 2 2 2 2 2 2 16 120 100 130 97 15 N 1 2 N N 1 1 1
89 Janani 714448c 1 17 2 2 2 2 2 2 17 120 120 96 96 15 N 1 2 N N 1 1 1
90 Vasu 523272b 2 34 1 2 2 2 2 2 17 120 120 96 96 15 N 1 2 N N 1 1 1
91 Chithra 734334c 2 29 2 2 2 2 2 2 17 70 120 92 98 15 N 1 2 N N 1 1 1
92 Prabhu 780485c 1 39 1 1 2 1 1 2 17 180 110 100 97 15 N 1 2 N N 1 1 1
93 Saravanan 411109c 1 18 1 2 2 1 1 2 17 220 110 108 98 15 N 1 2 N N 1 1 1
94 Sengamalar 863408c 1 37 2 2 2 2 2 2 17 210 160 102 99 15 N 1 2 N N 1 1 1
95 Sudhakar 812008c 2 26 1 2 2 2 2 2 17 210 130 92 99 15 N 1 2 N N 1 2 1
96 Thirumoorthy 823013c 1 25 1 2 2 2 1 2 17 135 110 85 96 15 N 1 2 N N 1 1 1
97 Dhanabackiam 863412c 2 70 2 1 2 2 2 2 17 180 180 120 96 15 N 1 2 N N 1 1 1
98 Shankar 289427c 1 33 1 2 2 1 1 2 18 120 120 90 96 15 N 1 2 N N 1 1 1
99 Dinesh 789956c 1 25 1 2 2 2 2 2 18 60 140 120 88 9 N 1 2 N N 1 1 1
100 Srinivasulu 839330c 2 16 1 2 2 2 2 2 18 210 110 100 97 15 N 1 2 N N 1 1 1
101 Rajesh 824798c 2 22 2 2 2 1 1 2 18 220 100 110 95 15 N 1 2 N N 1 2 1
102 Jayakumari 141617a 1 24 2 2 2 2 2 2 19 120 110 88 96 15 N 1 2 N N 1 1 1
103 Moorthy 850013c 1 40 1 2 2 1 1 2 20 210 110 124 94 15 N 1 2 N N 1 1 1
104 Anitha 876241c 1 17 2 2 2 2 2 2 4 160 140 100 96 15 N 1 2 N N 1 1 1
RIT IM APAC TR DMV DICU D.HS DIE DIAL PCM HB CREAT TC RBS NA K BIC LD PCHOL POUT TPN TRE TITPN SEP
2 2 8 2 5 N 5 1 2 2 14.8 1.2 11000 131 144 3.1 18 2 317 1 2 N 2 1
2 1 5 2 7 N 9 1 2 2 16.0 .8 15100 131 145 3.2 22 2 1460 2 N N N 1
2 N 15 2 3 N 3 1 2 2 19.7 1.1 13900 120 138 4.2 18 2 N 1 1 N 1 1
2 N 18 2 4 N 4 1 2 2 14.5 1.4 8600 128 143 3.8 16 2 N 1 1 N 1 1
2 N 23 2 3 3 3 1 1 1 13.7 4.7 15000 112 146 2.4 12 1 N 1 1 N 1 1
2 2 20 2 2 N 16 2 2 2 13.2 1.1 5200 80 141 4.0 16 2 1237 1 2 7 2 2
2 2 7 2 1 N 1 1 2 2 5.6 .7 17400 126 136 3.5 19 2 254 2 N N N 2
2 1 6 1 13 6 13 1 2 2 13.8 .8 13300 231 141 2.6 22 2 476 2 N N N 2
1 N 20 2 2 N 2 1 2 2 11.4 .7 8600 106 138 3.9 21 2 N 2 N N N 2
2 N 14 2 5 4 5 1 2 2 12.1 .8 15300 138 140 3.1 19 2 N 2 N N N 2
2 1 20 1 10 8 14 2 2 2 10.6 .8 13300 86 146 4.6 18 2 190 1 4 9 4 2
2 2 12 1 15 17 22 2 2 2 14.8 1.5 17700 287 137 3.0 19 2 317 1 3 14 3 1
2 1 9 1 14 16 23 2 2 2 19.3 1.0 21500 104 146 3.7 19 2 476 1 6 18 6 2
2 2 18 2 2 N 16 2 2 2 16.0 1.4 13800 144 148 3.1 16 2 381 1 2 10 2 2
2 2 18 1 12 14 20 2 2 2 16.5 .9 16400 108 136 4.0 17 2 508 2 N N N 2
1 1 16 1 20 21 24 2 2 2 17.9 1.2 15400 132 144 3.2 18 2 635 1 2 12 2 2
1 1 22 1 9 10 22 2 2 2 13.4 .9 14400 191 144 2.8 18 2 698 2 N N N 2
2 1 10 1 8 9 24 2 2 2 18.2 .8 17600 128 144 3.4 21 2 698 2 N N N 2
2 1 3 2 9 N 13 2 2 1 13.9 1.3 25100 134 145 3.3 24 2 825 2 N N N 2
2 1 7 2 8 6 10 1 2 2 15.4 1.0 13000 132 140 4.2 25 2 444 1 3 N 3 1
2 N 25 2 1 N 4 2 2 2 17.6 .9 11000 171 139 2.7 17 2 1237 2 N N N 2
1 N 8 2 7 9 12 2 2 2 10.2 1.0 25500 132 146 4.3 15 1 N 2 N N N 1
N N 4 2 N N 15 2 2 2 13.4 1.4 19700 97 139 3.2 22 1 N 2 N N N 2
2 N 20 2 9 11 12 2 1 2 12.4 .8 5900 193 138 3.5 19 2 N 1 1 12 1 1
1 N 9 2 7 7 12 2 2 2 11.7 .7 9500 109 133 3.7 24 2 N 2 N N N 2
N 2 4 2 N N 4 2 2 2 13.6 1.0 11200 117 139 4.7 21 2 381 2 N N N 2
N 2 12 2 N N 4 2 2 2 12.3 1.0 17200 171 136 3.5 18 2 190 2 N N N 2
N 2 9 2 N N 6 2 2 2 15.8 .7 11500 150 142 3.4 20 2 253 2 N N N 2
N 2 9 2 N N 5 2 2 2 10.1 .7 9600 85 143 3.1 19 2 254 2 N N N 2
N 2 2 2 N N 5 2 2 2 14.2 .9 10900 143 135 4.1 22 2 254 2 N N N 2
N 2 6 2 N N 6 2 2 2 17.0 .9 9400 89 141 3.9 21 2 286 2 N N N 2
N 2 5 2 N N 5 2 2 2 19.0 1.2 18100 119 144 4.4 22 2 317 2 N N N 2
N 2 6 2 N N 4 2 2 2 14.5 1.0 11600 168 144 3.0 21 2 317 2 N N N 2
N 2 5 2 N N 7 2 2 2 13.8 .8 8100 106 141 3.3 14 2 317 2 N N N 2
2 2 8 2 2 8 17 2 2 2 16.2 1.2 17200 170 136 2.9 19 2 317 2 N N N 2
N 2 6 2 N 1 6 2 2 2 13.2 .6 21100 110 140 3.7 20 2 349 2 N N N 2
N 2 5 2 N N 4 2 2 2 15.1 1.6 13600 106 148 3.0 22 2 381 2 N N N 2
2 2 22 2 4 3 6 2 2 2 13.3 .8 9800 140 140 2.6 17 2 412 2 N N N 2
N 2 6 2 N N 7 2 2 2 13.3 .8 7900 95 140 3.8 20 2 476 2 N N N 2
N 2 5 2 N N 4 2 2 2 16.9 1.0 14000 98 138 3.7 22 2 539 2 N N N 2
N 2 7 2 N N 4 2 2 2 17.4 .8 16500 108 136 3.1 21 2 571 2 N N N 2
N 2 6 2 N N 4 2 2 2 16.1 .9 16900 104 146 3.4 23 2 635 2 N N N 2
2 1 5 2 5 6 8 2 2 2 13.4 .7 8600 104 140 3.4 19 2 635 2 N N N 2
N 2 6 2 N N 4 2 2 2 11.6 .8 14700 120 142 3.1 21 2 730 2 N N N 2
N 2 8 2 N N 4 2 2 2 16.9 1.1 10900 90 136 4.1 20 2 984 2 N N N 2
2 1 4 1 21 20 29 2 2 2 14.3 .8 21600 140 142 3.8 21 2 984 2 N N N 2
2 2 8 2 3 3 5 2 2 2 15.8 .9 9700 125 143 4.3 21 2 2443 2 N N N 2
2 2 16 2 2 N 2 2 2 2 16.8 1.0 8200 102 133 4.0 21 2 3459 2 N N N 2
N 2 2 2 N N 2 2 2 1 15.6 .9 11900 128 143 3.6 22 2 5077 2 N N N 2
2 2 3 2 3 N 5 2 2 2 13.8 .6 13800 208 144 4.1 18 2 5394 2 N N N 2
N 2 8 2 N N 4 2 2 2 15.6 .7 9100 85 141 3.5 20 2 6124 2 N N N 2
N N 16 2 N N 4 2 2 2 17.6 1.2 9800 184 145 3.2 14 2 4664 2 N N N 2
N N 7 2 N N 3 2 2 2 15.0 .7 10200 120 142 3.8 19 2 N 2 N N N 2
N N 4 2 N N 2 2 2 2 13.4 .7 12800 106 138 3.4 16 2 N 2 N N N 2
N N 8 2 N N 3 2 2 2 15.2 .8 8200 81 136 2.4 21 2 N 2 N N N 2
N N 4 2 N N 2 2 2 2 17.1 .8 9600 110 135 3.9 27 2 N 2 N N N 2
N N 12 2 N N 3 2 2 2 13.5 .8 15300 140 138 4.1 21 2 N 2 N N N 2
N N 7 2 N N 2 2 2 2 10.5 .7 12900 132 141 3.3 17 2 N 2 N N N 2
N N 4 2 N N 2 2 2 2 14.1 .9 8800 140 138 3.5 19 2 N 2 N N N 2
N N 7 2 N N 2 2 2 2 14.9 1.2 10100 108 143 3.4 18 2 N 2 N N N 2
N N 8 2 N N 2 2 2 2 10.3 .8 17900 102 136 3.2 19 2 N 2 N N N 2
N N 4 2 N N 2 2 2 2 9.4 .7 10100 104 135 4.3 21 2 N 2 N N N 2
N N 9 2 N N 2 2 2 2 16.4 .8 8800 148 144 3.1 21 2 N 2 N N N 2
N N 7 2 N N 3 2 2 2 16.2 1.0 16900 100 148 3.3 21 2 N 2 N N N 2
N N 4 2 N N 3 2 2 2 13.2 1.4 10500 201 138 3.8 22 2 N 2 N N N 2
N N 8 2 N N 8 2 2 1 12.4 1.2 20200 194 138 3.6 15 2 N 2 N N N 2
N N 8 2 N N 3 2 2 1 17.3 .8 15000 132 146 3.0 22 2 N 2 N N N 2
N N 7 2 N N 7 2 2 1 15.2 .8 32500 142 136 4.5 20 2 N 2 N N N 2
N N 5 2 N N 4 2 2 2 14.9 .7 9400 104 146 3.0 23 2 N 2 N N N 2
N N 3 2 N N 7 2 2 1 13.2 .7 7800 98 143 3.5 23 2 N 2 N N N 2
N N 8 2 N N 4 2 2 1 11.5 .8 8400 114 135 4.4 21 2 N 2 N N N 2
N N 5 2 N N 5 2 2 1 9.3 .7 11600 148 133 3.1 17 2 N 2 N N N 2
N N 4 2 N N 2 2 2 2 12.2 .7 10200 108 136 4.0 16 2 N 2 N N N 2
2 N 5 2 3 5 8 2 2 1 13.5 .8 11600 88 143 4.0 20 2 N 2 N N N 2
1 N 3 2 N N 3 2 2 2 11.9 .6 6100 89 130 4.0 22 2 N 2 N N N 2
N N 10 2 N 1 3 2 1 2 12.6 .7 9800 80 134 3.1 10 2 N 2 N N N 2
N N 9 2 N N 3 2 2 2 13.5 .7 8800 85 134 3.6 20 2 N 2 N N N 2
N N 8 2 N N 3 2 2 2 13.5 .7 8800 128 134 3.6 20 2 N 2 N N N 2
N N 4 2 N N 5 2 2 2 14.1 .8 9100 127 135 3.9 20 2 N 2 N N N 2
N N 0 2 1 N 4 2 2 2 13.2 .8 3700 106 140 4.0 26 2 N 2 N N N 2
N N 4 2 N N 5 2 2 2 12.3 .8 8100 62 147 4.3 26 2 N 2 N N N 2
N N 3 2 N N 2 2 2 2 14.9 .7 14300 100 143 3.7 22 2 N 2 N N N 2
N N 12 2 N N 2 2 2 2 11.2 .7 5900 178 134 3.4 18 2 N 2 N N N 2
N N 7 2 N N 2 2 2 2 14.1 .8 9000 112 143 3.4 21 2 N 2 N N N 2
N N 7 2 N N 2 2 2 2 15.7 .9 13600 79 139 4.2 16 2 N 2 N N N 2
N N 8 2 N N 2 2 2 2 13.6 .7 8400 132 143 3.2 19 2 N 2 N N N 2
N N 4 2 N N 2 2 2 2 12.1 .6 5600 91 139 3.0 21 2 N 2 N N N 2
N N 12 2 N N 3 2 2 2 12.9 .9 19500 104 139 4.0 15 2 N 2 N N N 2
N N 5 2 N N 2 2 2 2 10.9 .6 12500 102 135 4.5 21 2 N 2 N N N 2
N N 4 2 N N 2 2 2 2 13.5 .9 7900 104 145 3.9 24 2 N 2 N N N 2
N N 4 2 N N 2 2 2 2 13.2 .8 8800 108 141 4.4 23 2 N 2 N N N 2
N 2 4 2 N N 3 2 2 2 16.1 1.3 10800 251 139 3.7 24 2 N 2 N N N 2
N N 7 2 N N 2 2 2 2 14.2 .9 7800 101 143 3.1 20 2 N 2 N N N 2
N N 5 2 N N 2 2 2 2 15.2 .6 16200 101 139 3.4 20 2 N 2 N N N 2
N N 5 2 N N 3 2 2 2 16.0 1.0 14400 118 141 3.4 17 2 N 2 N N N 2
N N 2 2 N N 2 2 2 2 15.4 .9 11200 96 143 3.5 20 2 N 2 N N N 2
N N 11 2 N N 2 2 2 2 13.4 .8 12400 203 140 3.5 20 2 5140 2 N N N 2
N N 8 2 N N 2 2 2 2 15.3 1.0 10200 132 141 3.8 19 2 N 2 N N N 2
N N 18 2 N N 2 2 2 2 16.1 1.1 12600 211 141 3.2 18 2 N 2 N N N 2
N N 5 2 N N 2 2 2 2 14.9 .9 15300 112 147 3.2 23 2 N 2 N N N 2
N N 3 2 N N 5 2 2 2 14.6 .9 10600 113 144 2.9 24 2 N 2 N N N 2
N N 3 2 N N 2 2 2 2 11.0 .8 13100 156 139 3.0 19 2 N 2 N N N 2
N N 10 2 N N 2 2 2 2 16.3 1.0 17800 137 140 3.2 22 2 3459 2 N N N 2
N N 3 2 N N 3 2 2 2 15.4 .7 9800 85 140 4.0 18 2 N 2 N N N 2
